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Abstract 
 The Plasma concentration of ketoconazole was assessed by 
estimation of the pharmacokinetic parameters for tow regimen 400 mg and 
800 mg in mycetoma patients. The study was carried out in the Mycetoma 
research center, Soba hospital, Faculty of Medicine at the University of 
Khartoum. Twelve patients adult were included in this study following 
fulfillment of the inclusion and exclusion criteria of the study. Open 
randomized design was performed. Blood samples were collected at specified 
hours after medication with ketoconazole (400 mg or 800 mg). Concentrations 
of ketoconazole were measured in Plasma by HPLC method. Non-
compartmental pharmacokinetic analysis was performed on the Plasma 
concentration-time data. 
 The pharmacokinetic parameters (Mean ± SD) of ketoconazole 
determined following administration of first and last dose 400 mg regimen 
were estimated as: T1/2 4.24 ± 1.87h and 8.60 h, Cmax 9.08 ± 3.96µg/ml and 
11.56 µg/ml, Tmax 2.33 ± 0.52 and 6 h, AUC 62.34 ± 31.03 and 183.07 µg.h/ml, 
MRT 8.15 ± 1.58 and 14.65 h, CL/F 8.78 ± 6.85 and 1.09 L/h, Vd/F 42.70 ± 
14.67 and 13.55 L. For first and last dose 800 mg regimen, the parameters 
were as follows: T1/2 4.00 ± 0.66 h and 6.83 ± 2.15 h, Cmax 17.21 ± 7.35 and 
18.44 ± 7.53 µg/ml, Tmax 2.17 ± 0.41 and 2.00 ± 0.82 h, AUC∞ 121.56 ± 71.52 
and 264.56 ± 136.96 µg.h/ml, MRT 7.86 ± 3.28 and 12.49 ± 5.29 h, CL/F 8.79 
± 5.57 and 3.18 ± 2.48 L/h, Vd/F 49.28 ± 27.11and 36.66 ± 40.14 L. 
The study concluded that the Plasma concentration of the tow 
regimens is highly comparable with that of the published studies. Our results 
support the concept of a change in pharmacokinetics with chronic dosing. 
High dose may lead to accumulation of ketoconazole in the body and might 
lead to toxicity 
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  اﻟﻤﻠﺨﺺ اﻟﻌﺮﺑﻲ
 اﻟﺪواﺋﻲ  ﺗﻢ ﺗﻘﻴﻴﻢ اﻟﺘﻤﺜﻴﻞ.ولزاﻟﻜﻴﺘﻮآﻮﻧﺎواﺋﻲ داﺧﻞ اﻟﺠﺴﻢ ﻟﻌﻘﺎر  اﻟﺘﻤﺜﻴﻞ اﻟﺪاﻷﻃﺮوﺣﺔ دراﺳﺔﺗﺸﻤﻞ هﺬﻩ 
  .اﻟﻤﻨﺸﻮرةداﺧﻞ اﻟﺠﺴﻢ ﻟﻬﺬا اﻟﻌﻘﺎر ﻋﻦ ﻃﺮﻳﻖ ﻣﻘﻴﺎس اﻟﺘﻮاﻓﺮ اﻟﺤﻴﻮي ﻟﻬﺬا اﻟﻌﻘﺎر وﻣﻘﺎرﻧﺘﻬﺎ ﺑﺎﻟﺪراﺳﺎت 
 ﺑﻤﺸﺎرآﺔ اﺛﻨﺎ اﻟﺨﺮﻃﻮم اﻟﻄﺐ ﺟﺎﻣﻌﺔآﻠﻴﺔ – اﻟﻤﻴﺴﺘﻮﻣﺎ ﻣﺴﺘﺸﻔﻰ ﺳﻮﺑﺎ أﺑﺤﺎث هﺬﻩ اﻟﺪراﺳﺔ ﺑﻤﺮآﺰ أﺟﺮﻳﺖ
اﺗﺒﻌﺖ .  ﺗﺤﻘﻴﻖ ﻣﻘﺎﻳﻴﺲ اﻟﺘﻀﻤﻴﻦ واﻻﺳﺘﺜﻨﺎء ﻟﻬﺬﻩ اﻟﺪراﺳﺔﺑﺎﻟﻤﻴﺴﺘﻮﻣﺎ ﺑﻌﺪﺮﺿﻰ اﻟﻤﺼﺎﺑﻴﻦ ﻋﺸﺮ ﻣﻦ اﻟﻤ
ﺗﻢ اﺧﺬ ﻋﻴﻨﺎت اﻟﺪم ﻓﻲ أوﻗﺎت ﻣﺤﺪدة ﺑﻌﺪ اﺧﺬ .  ﻃﺮﻳﻘﺔ اﻻﺧﺘﻴﺎر اﻟﻌﺸﻮاﺋﻲ اﻟﻤﻔﺘﻮحاﻹآﻠﻴﻨﻴﻜﻴﺔاﻟﺘﺠﺎرب 
  .(CLPH)اﻟﻜﺮوﻣﺎﺗﻮﻗﺮاﻓﻲ  ﻓﻲ اﻟﺒﻼزﻣﺎ ﺑﻮاﺳﻄﺔ اﻟﺘﺤﻠﻴﻞ ولزاﻟﻜﻴﺘﻮآﻮﻧﺎﺗﻢ ﻗﻴﺎس .ﺟﺮﻋﺔ ﻣﻦ اﻟﻌﻘﺎر
 ﻣﻠﻴﺠﺮام ﺣﺒﻮب ﻟﻠﺠﺮﻋﺔ 004 ولزاﻟﻜﻴﺘﻮآﻮﻧﺎاﻟﺨﻄﺎء اﻟﻤﻌﻴﺎري ± اﻟﻤﺘﻮﺳﻂ )ﺗﻢ ﺣﺴﺎب ﺣﺮآﻴﺔ اﻟﺪواء 
 ﺳﺎﻋﺔ  06.8 و  78.1 ± 42.4 ﻓﺘﺮة ﻧﺼﻒ ﻋﻤﺮ اﻟﺪواء ﺗﺴﺎوي : اﻷوﻟﻰ و اﻟﺠﺮﻋﺔ اﻻﺧﻴﺮﻩ آﺎﻵﺗﻲ
ﺣﻈﺔ ﻣﻞ واﻟﺰﻣﻦ اﻟﻼزم ﻟﻤﻼ/ﻣﺎﻳﻜﺮوﺟﺮام 11.9  و69.3 ± 80.9وأﻋﻠﻰ ﺗﺮآﻴﺰ ﻓﻲ اﻟﺒﻼزﻣﺎ ﻳﺴﺎوي 
 30.13 ± 43.26 واﻟﻤﺴﺎﺣﺔ ﺗﺤﺖ اﻟﻤﻨﺤﻨﻰ ﺗﺴﺎوي  ﺳﺎﻋﺔ 6و    25.0 ± 33.2 أﻋﻠﻰ ﺗﺮآﻴﺰ ﻳﺴﺎوي 
 و  85.1 ± 51.8ﻣﻞ وﻣﺘﻮﺳﻂ ﻓﺘﺮة ﺑﻘﺎء اﻟﺪواء ﻓﻲ اﻟﺠﺴﻢ ﻳﺴﺎوي /ﺳﺎﻋﺔ.ﻣﺎﻳﻜﺮوﺟﺮام 70.381و
ﺳﺎﻋﺔ وﺣﺠﻢ / ﻟﺘﺮ 90.1 و 58.6 ± 87.8  ﺳﺎﻋﺔ وﻣﻌﺪل ﺑﻘﺎء اﻟﺪواء ﻓﻲ اﻟﺠﺴﻢ ﻳﺴﺎوي  56.41
  .ﺑﺎﻟﺘﺮﺗﻴﺐ  ﻟﺘﺮ 55.31 92و  76.41 ± 07.24 اﻟﺪواء ﻳﺴﺎوي اﻧﺘﺸﺎر 
ﻓﺘﺮة ﻧﺼﻒ ﻋﻤﺮ :  اﻻﺧﻴﺮﻩ آﺎﻧﺖ آﺎﻵﺗﻲاﻟﺠﺮﻋﺔ و اﻷوﻟﻰ ﻟﻠﺠﺮﻋﺔ ﻣﻠﻴﺠﺮام ﺣﺒﻮب 008  ل ﺑﺎﻟﻨﺴﺒﺔ
 ± 12.71 ﺳﺎﻋﺔ وأﻋﻠﻰ ﺗﺮآﻴﺰ ﻓﻲ اﻟﺒﻼزﻣﺎ ﻳﺴﺎوي  51.2 ± 38.6 و 66.0 ± 00.4 اﻟﺪواء ﺗﺴﺎوي 
 ± 71.2ﻣﻞ واﻟﺰﻣﻦ اﻟﻼزم ﻟﻤﻼﺣﻈﺔ أﻋﻠﻰ ﺗﺮآﻴﺰ ﻳﺴﺎوي /ﻣﺎﻳﻜﺮوﺟﺮام 35.7 ± 44.81  و  53.7
 ± 65.462 و  25.17 ± 65.121ﺳﺎﻋﺔ واﻟﻤﺴﺎﺣﺔ ﺗﺤﺖ اﻟﻤﻨﺤﻨﻰ ﺗﺴﺎوي 28.0 ± 00.2 و  14.0
 94.21 و  82.3 ± 68.7ﻣﻞ وﻣﺘﻮﺳﻂ ﻓﺘﺮة ﺑﻘﺎء اﻟﺪواء ﻓﻲ اﻟﺠﺴﻢ ﻳﺴﺎوي /ﺳﺎﻋﺔ.ﻣﺎﻳﻜﺮوﺟﺮام 69.631
    ﺳﺎﻋﺔ/ﻟﺘﺮ 84.2 ± 81.3   و  75.5 ± 97.8ﺎوي ﺳﺎﻋﺔ وﻣﻌﺪل ﺑﻘﺎء اﻟﺪواء ﻓﻲ اﻟﺠﺴﻢ ﻳﺴ   92.5 ±
   .ﺑﺎﻟﺘﺒﺎدل ﻟﺘﺮ  41.04 ± 66.63   و  11.72  ± 82.94 وﺣﺠﻢ اﻧﺘﺸﺎر اﻟﺪواء ﻳﺴﺎوي
 اﻟﻤﺨﺘﺒﺮة ﻳﻤﻜﻦ ﻣﻘﺎرﻧﺘﻪ ﺑﺼﻮرة ﻠﺠﺮﻋﺎت أن اﻟﺘﻤﺜﻴﻞ اﻟﺪواﺋﻲ داﺧﻞ اﻟﺠﺴﻢ ﻟإﻟﻰﺧﻠﺼﺖ اﻟﺪراﺳﺔ   
وهﺬﻩ اﻟﺪراﺳﻪ ﺗﻌﺰز ﻣﻦ ﻓﻜﺮة ﺗﺮاآﻢ هﺬا ﻌﻴﺔ آﺒﻴﺮة ﻣﻊ اﻟﺘﻤﺜﻴﻞ اﻟﺪواﺋﻲ داﺧﻞ اﻟﺠﺴﻢ ﻟﻠﻤﺴﺘﺤﻀﺮات اﻟﻤﺮﺟ
   (. ﻣﻠﺠﺮام004  >) وﺧﺎﺻﺔ ﻋﻨﺪ اﺳﺘﻌﻤﺎل اﻟﺠﺮﻋﺎت اﻟﻜﺒﻴﺮﻩ اﻟﺪواء ﻓﻰ اﻟﺠﺴﻢ ﻋﻨﺪ اﻻﺳﺘﻌﻤﺎل اﻟﻤﺰﻣﻦ
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1. Introduction and literature review 
 
Mycetoma is a major mycological health problem in tropical and 
subtropical areas. 
Mycetoma is a chronic progressive subcutaneous granulomatous 
infection caused by tissue fungi or aerobic actinomyceas and hence it is 
divided into eumycetoma and actinomycetoma respectively (Mahgoub, 1989). 
Mycetoma is characterized by tumefaction and formation of sinus 
tracts. The sinuses usually discharge purulent and seropurulent exudates 
containing grains. It may spread to involve the skin and the deep structures 
resulting in destruction, deformity and loss of function (Hay et al, 1992 and 
Mariat et al, 1977). French missionaries in Ponchicherry in India first recorded 
mycetoma in 1812; it was noticed there since 1714 (Corre, 1883). Gill (1842) 
of Madurai dispensary in Madras province, in Southern India, is frequently, 
mistakenly quoted as the first reporter of mycetoma in the medical literature. 
He described this condition as “a foot covered with large fungoid excrescence 
discharging an offensive ichorous fluid “(Gill, 1874). 
In Sudan Madurella mycetomatis a true fungus, is the most common 
organism encountered (Fahal and Hassan, 1992). 
 
1.1 The Etiology and Epidemiology of Mycetoma 
 
Mycetoma is a chronic, relatively painless subcutaneous granuloma 
characterized by the formulation of multiple sinuses through which grains are 
discharged, the color of which depends on the etiological agents.  
Mycetoma classified into two groups: Eumycetoma caused by tissue 
fungi and Actinomycetoma caused by aerobic actinomycetoma, which are 
higher filamentous bacteria. According to some workers a third group is 
classified Botryomycosis, which is caused by bacteria.  
Various fungi, which produce grains of different sizes, colors and 
consistency, can cause Eumycetoma depending on the causative organisms. 
The most common ones include Madurella mycetomatis, Madurella grisea, 
Leptosphaeria senegalensis, Pyrenochaeta romeroi, and Curvularia lunata.  
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Actinomycetoma are mainly caused by aerobic actinomycetes which 
include Streptomyces somaliensis, Actinomadura madurae, Actinomadura 
pellitieri, and Nocardia species  
The disease occurs in many parts of the world but more common in the 
tropical and subtropical countries of Africa, the Middle East and other parts of 
Asia and South America (Mariot et al, 1977). 
Although India is considered as the birthplace of mycetoma yet the 
interest in mycetoma research had shifted at the turn of the century to the 
African subcontinent (Fahal, 1995). Gemy and Vincent form Algeria reported 
the first African case of mycetoma probably contracted the infection when he 
was in Tunisia. They isolated an aerobic actinomycete and streptothrix 
madurea (Actinomadura madurae) (Laveran, 1906). Pinoy in 1913 was the 
first to study actinomycotic agents and classified mycetoma organisms into 
two main groups the actinomycetes and the filamentous (true fungi) (Pinoy, 
1913).  Archibald in the Sudan in 1916 classified the etiological agents of 
mycetoma into two forms, eumycetes causing maduromycosis and 
pseudomycetes causing actinomycetoma (Chalmers and Archibald, 1916, 
Chalmers and Christopherson, 1916 and Chalmers and Archibald, 1918). 
Chiefly through the works of Mackinnon of Uruguay and the scientists of the 
Pasteur Institute in Paris, and Daker, the taxonomy of the causal fungi and 
actinomycetes had been considerably clarified (Mackinnon, 1954). 
There is mycetoma belt, which lies between Latitudes 15° south and 
30° north of the equator. Where there is a higher incidence of Savannah 
region than desert or tropical forests. In this region most of the rain falls during 
a season lasting 3-4 months. The remaining 8-9 are hot and dry which favor 
the growth of Acacia trees, which have big thorns that may play a role in 
introducing the organisms from soil into the body.  
The belt includes Sudan, Somalia, Senegal, India, Yemen, Mexico, 
Venezuela, Columbia, Argentina and others (Mahgoub and Murray, 1973, 
Mariot, 1963 and Magana, 1984). In Africa, mycetoma is most frequently seen 
in Sudan, Senegal, Mauritania, Kenya, Niger, Nigeria, Ethiopia, Chad, 
Cameroon, Djibouti and Somalia (Abbot, 1956 and Lynch, 1964). 
In Africa most mycetoma cases are eumycetoma caused mainly by 
Madurella mycetomatis. This is the most common agent of mycetoma in 
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Sudan, India and other tropical areas of Africa, but less in Somalia, Yemen 
and Saudi Arabia.  
Actinomycetoma is more common than Eumycetoma in the Niger 
where the diseases prevails.  
In the Northern deserts zone, the disease is predominantly caused by 
Streptomyces somaliensis, where as in the southern part, it is caused by 
Actinomadura pellitieri, followed by Nocardia brasiliensis and Actinomadura 
madurae in descending order of frequency (Develoux et al, 1985). 
Streptomyces somaliensis is seen more often in the Middle East, 
Central and West Africa and the arid region adjacent to the Sahara desert. 
Actinomadura pellitieri is more prevalent in the relatively humid areas. 
Nocardia are usually the causative organisms of mycetoma in temperate 
regions. Few cases have been reported in Upper Egypt and where all caused 
by M. mycetomatis (El-Mofti et al, 1965). 
In central Europe, the disease is rare but cases have been reported 
from Italy and Romania. 
The most common case of eumycetoma in the USA is Petriellidium 
boydii, which have been isolated from soil in the USA and Canada. 
 
1.2. Mycetoma in Sudan 
 
Mycetoma seems to have been known in Sudan before the advent of 
modern medicines, by its present common name of “Nebit” meaning growth. 
“Fakkis” practiced treatment by cauterization and/or amputation during the 
time of the Mahdeya (1885- 1899) (Mahgoub, 1994). 
Balfouer published the first documented report of a case of mycetoma 
in Sudan in 1904 (Balfouer, 1904) 
In 1931, Grantham–Hill, the senior surgeon at Khartoum Hospital made 
a detailed clinical study of 184 cases out of which 64% were of the black 
variety and 36% were yellow. Noting that the yellow type is actinomycotic and 
the black type is maduromycotic, he discussed the relative virulence of the 
two types. He doubted the value of medical treatment by various drugs 
suggested up to that date. He thought that the best routine treatment was 
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surgical, and that the key to success lies in early recognition and complete 
removal. 
Grantham–Hill (1931) was aware that amputations will deter patients 
from attending to hospital and therefore encouraged early detection. He 
therefore, defended local removal as much as possible. In his series of 184 
cases, 141 (77%) were treated by local removal and 43 (23%) by amputation. 
He gave support to the common belief that “Nabit” usually follows a thorn 
prick by saying that in 30% of his patients with mycetoma of less than six 
months duration; thorns were actually found embedded in the growth after 
removal at operation.  
Dr. Albert Chalmers, Director of Wellcome Tropical Research 
Laboratories, later known as Stack Laboratories and then the present day 
National Health Laboratories Khartoum, to gather with Captain R.G Archibald, 
pathologist, and Dr. J.B. Christopherson, Director of Khartoum and 
Omdurman Civil Hospital, carried out extensive studies of two causal 
organisms. Chalmers and Archibald gave quite an elaborative and specific 
definition of mycetoma as “All growth and granulations producing 
enlargement, deformity and destruction in any part of man, brought about by 
the invasion of the affected area by certain species of fungi belonging to 
different genera which gave rise to variously colored and shaped bodies 
called “ grains” which were formed of hyphae with or without chlamydospore, 
and are found either embedded in the pathological tissue forming the growth 
and granulation or escaping in the in the discharge from the diseased area” 
(Chalmers and Archibald,1916). 
For the first time Chalmers and Archibald introduced the terms 
Maduromycosis and Actinomycoses, preceded afterwards to classify the 
mycetoma into Maduromycetoma the grains of which are composed of large 
segmented mycelia and Actinomycetoma with grains composed of fine non- 
segmented filaments (Chalmers and Archibald, 1918).  
Abbott carried out in vitro trials with antibiotics against Madurella 
mycetomatis and Streptomyces somaliensis. He found that the growth of M. 
mycetomatis was unaffected by chloramphenicol, oxytetracycline, carbomycin 
and polymyxin B. While S. somaliensis was markedly sensitive to these 
antibiotic except Polymyxin B (Abbot, 1956 and Mahgoub, 1994). 
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Abbott noted that atrophic and neurological changes were absent in 
mycetoma and on dissection of some of the mycetomatis; glistening white 
tendons and nerves lay unaffected in the middle of damaged tissue.  
In 1964 Mahgoub published for the first time an article on the 
serological diagnosis of mycetoma. He also obtained a Ph.D. in 1965 on 
Mycotic infections in Sudan, the major part of which was mycological and 
serological study of mycetoma (Mahgoub, 1965). 
The late Mr. Ibrahim Moghraby (1967) who worked for many years as a 
surgeon in Wad Madani Hospital, center of endemic area for mycetoma, 
presented to the 6th Arab Medical Conference in Khartoum a study on 
“Mycetoma in the Gazira, a Public Health Problem” (Mohgraby, 1967). 
Heinemann Medical books of London in 1973 published a monograph 
on mycetoma written by Mahgoub and Murray. 
In Sudan, Madurella mycetomatis accounts for 71.4% of all mycetoma 
cases, Streptomyces somaliensis for 18%, Actinomadura madurae 5.3% and 
Actinomadura pellitieri for 2.7% (personal observations, Gumaa. SA) (Figure 
1-1). 
M. 
mycetomatis
71.40%
A. madure
5.30%
S. somaliensis
18%
A. pelletieri
2.70%
 
Figure 1.1. Distribution of mycetoma agents in Sudan 
Since mycetoma agents have been isolated from soil and vegetation in 
endemic areas, naturally the diseases prevails in those people who come in 
direct contact with the soil like farmers, cultivators, wood cutters, and 
herdsmen, but no occupation is exempted. 
In Sudan, males are affected more than females in the ration of 5:1 
(Abbott, 1956) (Figure 1-2). 
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Figure 1.2. Gender distribution of mycetoma in Sudan 
This is genuine gender difference and is not related to the great or 
outdoor activities of males because in certain areas of Sudan, males and 
females go out to work in the fields side by side. The disease is more 
common between the age group 20-40 years; this being the earning group, 
but no age is immune. 
The problem of treating mycetoma due to Madurella mycetomatis 
remained unsolved for quite a time, and once more success of treatment with 
Ketoconazole was reported form Sudan and Saudi Arabia by Mahgoub and 
Gumaa (1984) (Mahgoub and Gumaa, 1984) in a series of thirteen patients 
five were cured and four were greatly improved by daily intake of 
Ketoconazole. 
Since then, many environmental, social and economical changes have 
taken place. Global variation in the pattern of mycetoma and changes in the 
disease spectrum over the years are well documented in the literature. Never 
the less, there is a need for periodic studies of mycetoma to define these 
changes so as to improve the management of mycetoma patients.  
Mycetoma lesions are amenable to surgical excision but the recurrence 
rate is high. Advanced cases usually require prolonged medical treatment. 
However, in spite of the use of conventional therapeutic doses for a long 
duration, the response to medical treatment in many patients especially those 
with eumycetoma is delayed and far from satisfactory (Mahgoub, 1976 and 
Welsh et al, 1987). Possible factors that influence the effectiveness of 
chemotherapy in mycetoma include the sensitivity of the organism to the drug, 
drug Pharmacokinetics and the local blood supply to the lesion. 
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Actinomycetoma due to Actinomadura pellitieri is an uncommon 
infection, accounting for less than 3% of all mycetoma cases in the Sudan 
(Fahal and Hassan, 1992). 
The subject of Mycetoma since then became the focus of study for 
some Sudanese researchers where intensive investigations had been carried 
out (Fahal, 1994). 
 
1.3. Route of entry 
 
The organisms are usually present in the soil in the form of grains. 
After they are moistened by rain, they form conidia or other forms able to 
infect the host. This infecting agent is then implanted into the host tissue 
through a breach in skin produced by trauma caused by sharp object such as 
thorn pricks, stone or splinters. However, in many patients there is no history 
of trauma at the site of infection. In areas where mycetoma is frequent the 
habit of going barefooted is common and thorns are plentiful. As a result, 
natural infection is expected to be more frequent than it actually is, if this 
theory of route of infection is true. The disease is not contagious from person 
to other or from animal to human (Mahgoub and Murray, 1973, Abbott, 1956 
and Lynch, 1964).  
 
1.4. Incubation period 
 
The rate of progress is more rapid with actinomycetoma than with 
eumycetoma. In eumycetoma, the lesion grows slowly with clear defined 
margins and remains encapsulated for a long period, whereas, in 
actinomycetoma the lesion is more inflammatory, more destructive and 
invades the bone at an earlier period (Gonzalez, 1975, Hay et al, 1992, El 
Moghraby, 1971 and Grantham- Hill, 1968). The incubation period in 
mycetoma is unknown due to the difficulty in establishing the time of initial 
infection however in experimental animals the formation of the granuloma was 
noted after a period of three weeks from the inoculation of the organism 
(Mahgoub and Murray, 1973, Magana, 1984 and Lynch, 1964). 
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1.5. Mycetoma immunology 
 
Antibodies against mycetoma organisms usually develop after the 
infection. They are of two types, the precipitating and complement fixed ones. 
The antibodies rise with the disease activity, decline with recovery and 
disappear with cure. They can be used for the diagnosis of mycetoma, 
identification of the individual organism and follow up of patients on medical 
treatment (Gordon and Hagan, 1936). 
 
1.6. The Pathology of Mycetoma 
 
Mycetoma (maduromycosis) is a chronic granulomatous subcutaneous 
infection caused by actinomycete (actinomycetoma) or by true fungi 
(eumycetoma). It is characterized by the formation of aggregates of the 
organism (grains) in the tissues, which are visible to the naked eye. The 
grains vary in color, size and consistency depending on the mycetoma 
causative agent (Figures 1-3 to 1-6). 
 
Figure 1.3. Mycetoma of the foot 
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Figure 1.4. Mycetoma of the hand 
 
 
 
 
 
 
Figure 1.5. Mycetoma of the head 
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Figure 1.6. Mycetoma of the face 
 
Both actinomycetoma and eumycetoma prevail in the Sudan. 
Eumycetoma due to Madurella mycetomatis is the most common type 
(Mahgoub and Murray, 1973 and Lynch, 1964). 
The actinomycetoma is commonly caused by Streptomyces 
somaliensis, Actinomadura madurae and Actinomadura pellitieri. 
 
1.7. Clinical Presentation of Mycetoma  
 
Mycetoma is seen in males more frequently than in females with a ratio 
of 5:1. This is a genuine difference and it is not related to the outdoor activities 
as was previously considered, due to the fact that in endemic areas, females 
are committed in outdoor activities as much as males (Mahgoub and Murray, 
1973 and Cameron et al, 1973). No age is exempted but mycetoma 
commonly affects adults between 20-40 years of age, the earning members of 
the society. 
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Mycetoma is seen more conventionally in cultivators, field laborers and 
in herdsmen who come in contact with the land as seen in Africa nomads and 
the Arabian Peninsula (Mahgoub and Murray, 1973 and Abbot 1956). 
The duration of the disease at presentation varies between three 
months to 30 years, patients tend to present late with advanced disease. This 
may be due to the nature of the disease, which is painless and slowly 
spreading and lack of health education. 
The rate of progress is more rapid with actinomycetoma than with 
eumycetoma. In eumycetoma, the lesion grows slowly with clearly defined 
margins and remains encapsulated for a long period whereas in 
actinomycetoma the lesion is more inflammatory, more destructive and 
invades the bone at an earlier period (Mahgoub and Murray, 1973, Chadfeild, 
1964 and Manson 1987). This is clearly seen in infection with Actinomadura 
pellitieri which is more cellular, infiltrative destructive and it is a potent 
osteophytic agent (Culligan et.al, 1985 and Kamalam and Thambiah, 1987). 
This is also observed with Nocardia brasiliensis (Hogshead and Stein, 1970). 
One or a combination of the following factors may influence the clinical picture 
of mycetoma, duration of the disease, causative organism, site of infection 
and immune response of the host. 
The characteristic triad of a subcutaneous nodule, sinus and the 
presence of grains are pathogonomic of mycetoma. It presents as a slowly 
progressive painless subcutaneous swelling at the site of previous trauma 
(Mahgoub and Murray, 1973, El Moghraby 1971 and Grantham–Hill, 1934). 
The swelling is usually firm and rounded but it may be soft, lobulated, and 
rarely cystic and it is often mobile.  
Mycetoma is usually painless in nature because it is assumed that the 
organism produces substances, which have an anesthetic action (Gumaa, 
1983). In about 18% of cases, patients may seek medical advice for the pain, 
which may be produced by the expansion of the bone with the mycetoma or 
due to secondary bacterial infection (Fahal and Hassan, 1992). 
For unknown reasons, the tendons and the nerves are curiously spared 
until very late in the disease process, this may explain the rarity of 
neurological and atrophic changes in mycetoma (Gumaa, 1974).  
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The most common site for mycetoma is the foot (Figure 1-3) which 
accounts for 70% of cases, most of the lesions are seen on the dorsal aspect 
of the forefoot and for unexplainable reasons the left foot is more affected 
(Mahgoub and Murray, 1973, Magana, 1984, Abbot, 1956 and Fahal and 
Hassan, 1992). The hand (Figure 1.4) is the next common site, which occurs 
in 12% of cases (Murray IG, 1960 and Tight and Bartlell, 1981). In endemic 
areas other parts of the body may be involved but less frequently, the knee, 
arm, leg, head and neck (Figure 1.5), thigh and the perineum are affected in 
that order (Soretain et al, 194 and Brijesh et al, 1984). Rare sites such as the 
chest, abdominal wall, facial bones (Figure 1.6), mandible, testes, paranasal 
sinuses, eyelid and surgical incisions may be affected (Aldrige and Kirk, 1940 
and Fahal et al, 1994). 
foot
70%
Hand
12%
Other parts
18%
Figure 1.7. Most common sites for mycetoma 
 
Mycetoma in general involves those parts of the body that come in 
contact with soil during standing, sitting or lying down. Visceral mycetoma had 
not been reported yet. 
 
1.8. Medical Treatment of Mycetoma 
 
The morbidity of mycetoma in Sudan has not changed and perhaps 
more than 400 new cases are seen in hospitals and outpatient clinics every 
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year (Sudan medical journal, 1994). Similarly the outcome of surgical 
treatment alone has remained as leading to 80% recurrence rate. The quest 
for effective medical treatment was therefore actively perused. In vitro tests 
with antibiotics were carried out on mycetoma organisms for the first time in 
Sudan in 1956 (Abbot, 1956). At the same time there were reports of 
successful medical treatment with chemotherapeutic agents of mycetoma 
caused by Nocardia brasiliensis from Mexico (Gonzalez–Ochoa, 1955). 
Against this background the mycetoma Clinic at Khartoum North Civil Hospital 
was established in 1968, in order to conduct clinical trials of current and the 
would be available drugs. 
Prior to starting medical treatment it is absolutely necessary to 
determine whether the causal organism of the mycetoma is a bacterium 
(actinomycetoma) or a fungus (eumycetoma). Many failures are attributed to 
giving the treatment of one to the other. 
It is as well worth noting that surgical reduction of a bulky swelling 
without affecting the function of an affected bony lesion will certainly reduce 
the length of treatment. 
 
1.8.1. Treatment of Eumycetoma 
 
In many centers, surgery is the most acceptable line of treatment for 
eumycetoma cases: in the form of aggressive surgical excision or amputation 
in advanced disease (Mahgoub and Murray, 1973, Magana, 1984 and Lynch, 
1964). 
Reports of medical treatment in eumycetoma are few (Murray and 
Colichon, 1962). Various antifungal agents have been tried with little success. 
This is perhaps surprising, as the fungi causing eumycetoma are low-grade 
pathogens and their eradication should be readily achieved by the 
administration of safe systemically active agent (Murray and Colichon, 1962). 
Amphotericin B has been used with limited success and it is no longer popular 
due to its toxic side effects (Mahgoub and Murray, 1973).   In the case of 
eumycetoma due to Madurella mycetomatis, which constitutes the major 
causative agent in tropical and subtropical Africa and Asia, the drug of choice 
is ketoconazole (Mahgoub and Gumaa, 1984). 
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A number of studies showed that ketoconazole could cure 
eumycetoma patients. Mahgoub and Gumaa reported, in 1984, impressive 
results in treating thirteen patients with confirmed eumycetoma. Five of them 
were cured, two of these patients had bone involvement, four patients showed 
considerable improvement with ketoconazole. The dose for the cured patients 
was 300- 400 mg daily, while the dose for those who improved was only 200 
mg daily. 
Treatment of these patients continued for periods ranging from three 
months to three years (Mahgoub and Gumaa, 1984). 
In a dose of 200 mg twice daily, no significant side effects or 
biochemical abnormalities are seen. Ketoconazole is, however, not effective 
in mycetoma caused by Petriellidium boydii or Acremonium species (Hay et 
al, 1992). Liver function tests are regularly carried out every month during 
treatment.  
Other regimes include procaine penicillin in a dose of 600000-800000 
units per day given intramuscularly and griseofulvin in a dose of 500 mg three 
times a day given orally. 
 
1.8.2. Treatment of Actinomycetoma 
 
Actinomycetoma is amenable to medical treatment with antibiotics and 
other chemotherapeutic agents. Combined drug therapy is always preferred to 
a single drug (Hay et al, 1992, Mahgoub, 1976 and Mahgoub and Murray, 
1973). Standard treatment is a combination of streptomycin and 
cotrimoxazole, but if there is no response, a combination of streptomycin with 
one of the following drugs is given: dapsone, sulphadoxine-pyrimethamine 
(Fansidar®) and rifampicin. It is reasonable to start with a combination of 
streptomycin sulphate in a dose of 14 mg/kg daily for one month then on 
alternate days and diaminodiphenyl sulphone (dapsone) in a dose of 1.5 
mg/kg twice daily for patients with Streptomyces somaliensis, Actinomadura 
madurae, and Nocardia species. If there is no response for few months or if 
there was persistent side effect then dapsone is replaced by Co- trimoxazole 
(Septrin®) in dose of 1.5 mg/kg twice daily (Mahgoub, 1972 and, 1976). 
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Actinomadura pellitieri usually resistant to the dapsone and the 
combination of choice is streptomycin sulphate and Septrin (Mahgoub, 1976). 
Whatever regimen is used, supportive treatment with ferrous sulphate and 
folic acid and regular follow up of patients for hemoglobin concentration and 
total white blood count must be provided. 
Treatment must be continued until the patient is clinically, serologically 
and radiologically cured. Clinical improvement is judged by reduction in the 
size of the mass and healing of the sinuses. Cure is considered when the skin 
becomes normal, the mass disappeared, the sinuses had healed and the 
organism is eliminated form the tissue. Photography of the lesion is usually 
offered every 3 months or less for follows up.  
Medical treatment should be given pre and post operatively as it 
facilitates surgery, accelerates healing and reduces the chance of relapse. 
The cure rate varies between 60-90% (Fahal and Hassan, 1992, Hay et al, 
1992, Mahgoub, 1976 and Mahgoub and Murray, 1973). 
Recurrence is more common after an incomplete course of medical 
treatment and there is a good chance for the organism to develop drug 
resistance.    
Actinomadura pellitieri responds better to combination of streptomycin 
and cotrimoxazole, whereas Actinomadura madurae responds better to 
streptomycin and dapsone. Nocardia asteroides, Nocardia brasiliensis and 
Streptomyces somaliensis respond to either drug combination. 
The drug of choice in the treatment of eumycetoma is ketoconazole. 
The length of treatment varies form 6-12 months depending on size of 
mycetoma and response to treatment.  
Mycoserology has been developed using techniques such as counter- 
immuno–electrophoresis (CIE), enzyme linked immunosorbent assay (ELISA) 
and immunodiffusion. These approaches are important.  
 
1.9. Surgical Treatment of Mycetoma 
 
In the Sudan Madurella mycetomatis, which is a true fungus, is the 
most common organism encountered. Streptomyces somaliensis, 
Actinomadura madurae and Actinomadura pellitieri are the most common 
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causative organisms for actinomycetoma (Fahal and Hassan, 1992). 
Mycetoma is endemic in the central part of the country and it is rarely seen in 
the South (Abbott, 1956 and Lynch, 1964). 
The disease presents as a localized tumor – like mass with or without 
sinuses. Mycetoma progresses slow eventually it leads to the destruction of 
the deep tissue and bone. The most common site is the dorsum of the foot 
hence the name “Madura foot”. However extra- pedal involvement is seen as 
well, it was reported in the hand, leg, head and neck, abdominal wall, buttock 
and perineum (El Moghraby, 1971 and Gumaa, 1983). 
Surgery for mycetoma ranges from local excision to mass reduction 
and occasionally amputation of the affected part. 
The aim of surgical treatment is complete removal of the lesion, this is 
possible in patients who have early disease in which the granuloma is 
localized and confined to the subcutaneous tissue (Mahgoub and Murray, 
1973). In patients with massive lesion, mass reduction is indicated, in these 
cases the involved soft tissue is excised and the bone is curettage. The 
technique greatly facilities the response to medical treatment. 
To avoid the socially disastrous consequences of amputation, a 
program of extensive repeated excision of the diseased tissue, including bone 
may be carried out preferentially (Bandl et al, 1987). This debunking 
procedure must be accompanied by mycetoma chemotherapy. 
The recurrence rate with surgery is high, ranging from 20 to 90 percent 
(Fahal and Hassan, 1992 and El Moghraby, 1971). Medical treatment before 
surgery is recommended to ascertain high level of the drugs in the circulation 
to minimize the chance of the organism local spread. In most cases medical 
treatment should continue until the patient shows clinical, radiological and 
serological evidence of cure. 
Eumycetoma is well encapsulated and great care must be exerted not 
to rupture the capsule to minimize the spread of grains along the fascial 
planes if recurrence is to be avoided. 
Actinomycetoma has an ill-defined border therefore a margin of health 
tissue should always be excised with the lesion. 
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1.10. Assessment of Progress and Follow up of Mycetoma Patients 
 
Both Subjective and objective criteria must be taken into consideration 
for the assessment of response to treatment. In the former, the patients’s own 
assessment of his progress as well as that of the nursing sister and the 
treating doctors is recorded. 
For the objectives criteria, patients are questioned about pain before 
and during treatment, and the number and activity of sinuses is recorded as 
well as the appearance of the skin. On examination, the skin is usually 
attached to the underlying tissue. When the patient starts to show clinical 
improvement the overlying skin becomes less fixed and the underlying mass 
becomes freely mobile. 
The circumference of the swelling is measured by means of a tape 
measure and whenever possible this is done at fixed bony prominences like 
the malleoli or at a measured distance from the tip of the toes. More 
permanent records are kept by taking photographs of the same view at a fixed 
distance before, at different intervals during, and at end of treatment. At about 
three months intervals radiographs of the affected lesion are taken to assess 
bone improvement. 
Sera are collected at monthly intervals and tested by means of counter-
immuno-electrophoresis (CIE). After staining with naphthalene black, both the 
number and intensity of the precipitation lines are recorded. A patient is 
considered cured when his serum becomes negatives and remains so in two 
successive precipitation tests (Mahgoub, 1985). 
 
1.11. Recurrence in Mycetoma 
 
Recurrence is either local at the site of previous lesion or at the 
regional lymph nodes. The postoperative recurrences rate in mycetoma 
various from 25 to 50% (Hay et al, 1992, Mahgoub and Murray, 1973 and 
Lynch, 1964). It is mainly due to inadequate removal of the organisms during 
surgery. 
Postoperative medical treatment is essential because if the treatment is 
stopped after apparent cure, recurrence may be immediate. Follow up of 
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patients with mycetoma must be long enough to detect early recurrence and 
to advise early treatment (Mahgoub, 1976). 
 
1.12. Mycetoma Research in Sudan 
 
The Sudan seems to be the homeland of mycetoma. Lynch in 1964 
estimated the incidence of mycetoma in the Sudan as 300 – 400 new hospital 
cases annually. This figure does not take into account the considerable 
number of outpatients and those seen at peripheral dispensaries where 
qualified doctors might not even be present. 
A mycetoma clinic at Khartoum North Civil Hospital was established in 
1968 in order to conduct clinical trials of current and potential drugs. 
Investigation, follow up and documentation of mycetoma cases in 
Sudan were made feasible by the establishment of the Mycetoma Research 
Center at Soba University Hospital (Fahal, 1994). The center provides 
diagnosis, medical treatment and follow up of mycetoma patients from almost 
all over Sudan. 
 
1.13. Antifungal Agents 
 
1. 13.1. Introduction 
 
Fungi live all around, they mainly exist in soil, converting lignin, chitin, 
keratin, and cellulose into humus, but they also grow on plants, thrive in the 
fur of pets, and help the body maintain normal functionality. These 
heterotrophic microorganisms can, however, cause serious illnesses, termed 
mycoses, in humans. Mycotic illnesses in humans are divided into two basic 
categories: systemic mycoses and superficial mycoses. The former are non-
contagious and can be quite serious. Examples include aspergillosis and 
blastomycosis. Superficial mycoses can be further divided into the categories 
of dermatophytic infections and candidosis. Dermatophytic infections affect 
the skin, hair, and nails. The fungi digest the keratin in the tissues just as they 
do in the soil. Scalp ringworm and athlete's foot are examples of this type of 
contagious infection. Candidosis affect moist skin and mucous membranes. 
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Candida albicans naturally exists in our gastrointestinal tract and aids in 
digestion, however this fungus can spread to other parts of the body, causing 
infection. An example is vaginal candidosis, which is only contagious to a 
fetus, should the infected woman be pregnant. 
The drugs used to treat mycoses are either applied topically at the site 
of infection, or delivered systemically. The major families of antifungal agents 
include antibiotics, antimetabolites, the azoles and synthetic allylamines. The 
key event of antifungal drug development is shown in figure 1-8. 
 
Figure1.8. Key events in antifungal drug development. 
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1.13.2. Antibiotics 
 
Various types of antibiotics have proven useful in controlling fungal 
infections. Griseofulvin was first obtained from Penicillium griseofulvum in 
1939 and has been used systemically to treat dermatophytes (Figure 1-9). 
Since it is administered orally, but because this drug is rather insoluble in 
water, absorption is very low. Taking the tablets with a high-fat meal is 
recommended as it increases absorption. 
It’s fungistatic, rather than fungicidal, activity is limited to actively 
growing dermatophytes, and it is most effective in the upper body where 
continuous reinfection is least common. Griseofulvin has a dual effect on 
fungal cells. First, it binds to the RNA, preventing replication. Secondly, it 
causes multipolar mitosis, producing abnormal nuclei and thus abnormal 
fungi. As a result of this action, hyphal penetration is substantially inhibited, 
allowing the outward thrust of keratinized host cells to deprive the fungi of the 
required nutrients. 
Side effects in humans include headache, allergic, neurological, and 
gastrointestinal reactions, and 1ncreases in feca1 protoporphyrin. It also 
induces hepatic microsomal enzymes, which retard the activity of oral 
anticoagulants. In addition, teratogenic and carcinogenic activity has been 
observed in lab animals. As a result, Griseofulvin is only used as a last resort 
for treating superficial dermatophyte infections. 
 
 
 
Figure1.9. Chemical structure of griseofulvin 
 
A class of antibiotics known as the polyenes is useful in the treatment 
of candidacies and systemic mycoses. Polyenes contain a large lactone ring 
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with four to seven unsubstituted, conjugated double bonds. These are usually 
in an all-trans configuration, creating a planar molecule. These compounds 
are rather insoluble in water, and, due to the vast amount of double bonds, 
somewhat reactive. amphotericin B and nystatin (Figures 1-10 and 1-11, 
respectively) are prime examples. Amphotericin B prevailed as the dominant 
treatment for systemic mycoses for more than two decades after its 
development in the 1950's. Due to its low absorption in the gastrointestinal 
tract, intravenous administration is necessary. Nystatin is toxic in the human 
body, thus it can only be applied topically. It has been very effective in treating 
superficial mycoses such as vaginal candidosis. 
 
 
 
Figure1.10. Chemical structure of amphotericin B 
 
 
Figure1.11. Chemical structure of nystatin 
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These antibiotics, being lipophilic, act by binding to sterols in the 
membranes of cells. This includes cholesterol in animal cells and ergosterol in 
fungal cells. When the molecules bind to the cell membrane, its permeability 
is altered. As a result, the cell can no longer control its internal environment-
ions and organic cell constituents can enter and leave uncontrolled. 
Fortunately, these compounds have a greater affinity for ergosterol than for 
cholesterol; however, severe side effects can occur: nausea, anoxeria, chills, 
fever, headache, anemia, phlebitis, hypokalemia, and azotemia. The greatest 
drawback, though, is its toxicity in the kidneys. When administered, the 
dosage must be carefully monitored so that no more is in the blood than is 
necessary. Lower dosages have also been given with 5-Fluorocytosine with 
positive effects (Figure 1-12). 
 
 
 
Figure1.12. Chemical structure of 5-flucytosine 
 
1.13.3. Antimetabolites 
 
Flucytosine (Figure 1-12) is a prodrug, which is highly effective, but 
only against a narrow spectrum of fungi, namely yeasts. It is applied 
systemically, where it is converted to 5-fluorouracil by a specific deaminase 
found only in yeast cells. As a result, this drug is highly selective. In addition 
to its high selectivity; this drug takes two courses of action against the 
infecting fungi. First, the 5-fluorouracil is incorporated into the RNA of the 
fungi as though it were uracil. This leads to severe genetic mutation. 
Secondly, the 5-fluorouracil is metabolized to 5-fluoro-2'-deoxyuridylate, which 
inhibits thymidylate synthetase, an enzyme necessary for the production of 
thymidine. Thymidine is required for DNA synthesis. These two mechanisms 
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make it a very effective agent for systemic treatments of Candida, 
Cryptococcus, and Torulopsis infections. 
This drug is typically taken orally, where it achieves rapid and complete 
absorption. It distributes throughout the body, including the cerebrospinal 
fluids, which explains its effectiveness against meningitis infections. 
Flucytosine is often given in conjunction with Amphotericin B. It is believed 
that the polyene damages the fungal cell wall sufficiently to allow more 5-FU 
in, expediting its desired effect. A major drawback of 5-fluorouracil is the rapid 
development of resistant strains - yet another reason to combine it with 
another treatment. 
As 5-fluorouracil is also an anticancer drug, the side effects can be 
rather strong. It can cause bone marrow depression (including leukopenia and 
anemia), gastrointestinal disturbances (such as nausea, vomiting, and 
diarrhea), and central nerves system toxicity (which can produce headache, 
drowsiness, and hallucinations). 
 
1.13. 4. Azoles 
 
The azole family consists of compounds containing one or more 
imidazole or triazole ring. 
The azoles quickly gained popularity, as they presented systemic and 
topical treatments effective against nearly all mycoses. Clotrimazole and 
miconazole (Figure 1-13), both developed in 1969, were the first imidazoles 
used in antifungal chemotherapy. 
 
Figure1.13. Chemical structure of miconazole 
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The azoles target a fundamental difference between mammalian and 
fungal cells-the production of the sterol used in the cell membrane. Sterols are 
of particular importance to cells, as they control the structure and permeability 
of the membrane. While mammalian cells use cholesterol, fungal cells have 
ergosterol. There is a common biosynthetic pathway shared by mammals and 
fungi up a certain point, and it is a specific step in the synthesis which the 
azoles block. 
Both mammals and fungi produce lanosterol and use a 14 α-
demethylase to begin converting it into their respective sterol. Fortunately, this 
enzyme is slightly varied between mammalian and fungal cells, allowing a 
modified azole the ability to select for fungal cells. Because the 14 α-
demethylase system is carbon dioxide sensitive, it requires cytochrome P-450 
to initiate the oxidation of the 14 α-methyl of lanosterol. At the core of 
cytochrome P-450 lays an iron molecule bound to four N molecules. It is to 
this iron molecule that the azole binds, destroying its oxidative potential. This 
thereby prevents the demethylation of lanosterol and thus ergosterol cannot 
be produced. Such inhibition leads to the breakdown of the fungal cell 
membrane. This mode of action is confirmed by the observation of an 
increased concentration of 14 α-methylsterols within treated fungal cells. 
Clotrimazole and miconazole both showed great activity as topical 
creams, but serious side effects (such as anemia and thrombocytosis) arose 
from systemic administration. In addition, much of the drug was lost through 
first-pass metabolism in the liver, and, due to its lipophilic nature, the drug 
would bind to proteins in the blood so that little was available to have its 
antifungal effect. The azoles, however, showed much promise, and other 
drugs were developed which were tolerated by our system and effective 
against infections. 
Ketoconazole was the next imidazole to become widely used, as it had 
the most widespread effect and the fewer side effects. This drug is available 
as a prescription table, a cream, or a shampoo, and represents a major step 
in systemic treatment of mycoses. Unlike its predecessors, ketoconazole is 
readily absorbed and delivered throughout the body. Some common side 
effects include headache and nausea, but more severe are its effects on 
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cholesterol and testosterone levels. Ketoconazole, in small doses, has been 
shown to lower cholesterol in humans, presumably because its specificity 
factors are not sufficient to distinguish between the mammalian and fungal 
enzyme systems. This drug has also been shown to inhibit adrenal 
corticosteroid and testosterone synthesis. As it has these effects, 
ketoconazole has actually been used to treat adrenal hyperplasia and cancer. 
All systems return to normal once treatment is stopped. 
Itraconazole and fluconazole (Figures 1-14 and 1-15, respectively) are 
two triazoles that represent the next major developments. 
 
 
 
Figure1.14. Chemical structure of itraconazole 
 
 
 
Figure1.15. Chemical structure of fluconazole 
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Itraconazole showed greatest activity against dermatophytic infections 
of the skin and nails, while fluconazole showed promise with yeast infections 
such as candidosis and Cryptococcal meningitis. Fluconazole is particularly 
noted for its lack of serious side effects and its compatibility with azithromycin 
(before fluconazole, AIDS patients had few if any options for dealing with 
fungal infections). One reason for this could be its relative stability in the 
system-the C-F bonds of the benzyl ring are quite strong and rather 
unreactive. Fluconazole is also a highly active antifungal agent-it is absorbed 
100% into the body and is 10-100 times more effective than ketoconazole. 
 
1.13.5. Synthetic Allylamines 
 
This family of antifungal agents was discovered in 1979 and presents 
many valuable advances. Terbinafine (Figure 1-16) is an example of an orally 
administered allylamine, and naftifine and pyridone ciclopirox are examples of 
a topical cream and gel. 
 
 
 
Figure1.16. Chemical structure of terbinafine 
 
The systemic drugs act by inhibiting squalene epoxidase, which 
converts squalene into squalene oxide. This oxidation represents the first step 
in the synthesis of ergosterol, which is a required constituent of the fungal cell 
membrane. In addition, squalene is toxic to the cell, and if it is not converted, 
the levels build up within the cell and rapidly kill it. The topical drugs act by 
accumulating within the cell and interfering with amino acid transport through 
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the cell membrane. This instability leads to cell death. These molecules also 
have the ability to penetrate into hair follicles and prevent reinfection. 
The allylamines are most effective against filamentous fungi, such as 
found in dermatophytic infections like Tinea corporis and Tinea unguum. 
Some of the great advantages of this drug over previous treatments include 
shorter term of treatment, fewer and milder side effects, fewer drug 
interactions, and greater potency. 
A Schematic description of sites of action of different antifungal agents 
is shown in figure 1-17. Candins cause disruption of cell wall, allowing other 
antifungals (polyenes, azoles, and 5-FC) to enter. Azoles and polyenes can 
inhibit or bind to ergosterol, leading to cell lysis and allowing 5FC to enter the 
cell and inhibit nucleic acid synthesis. Dashed arrows indicate the site of 
action for each antifungal class. The mechanisms of action for each class of 
antifungal agent are depicted in panels A through D. 
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Figure1.17. Schematic description of sites of action of different 
antifungal agents. 
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Ergosterol biosynthetic pathway and the steps at which various 
antifungal agents exert their inhibitory activities are explained in figure 1-18. 
 
 
 
Figure1.18. Ergosterol biosynthetic pathway, steps at which various 
antifungal agents exert their inhibitory activities 
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The pharmacologic targets of different antifungal agents are 
illustrated in figure 1-19. 
 
 
Figure1.19. Pharmacologic targets of antifungal agents 
 
As has been previously mentioned, the antibiotics act by interfering 
with mitosis or, in the case of the polyenes, by binding to the sterol in the cell 
membrane, altering its permeability. These drugs are moderately effective, but 
are highly toxic to humans. Flucytosine is metabolized by the fungus into 5-
flourouracil, which is then incorporated into RNA, disrupting DNA synthesis. 
This drug is rarely effective on its own as resistance emerges quickly; 
therefore, it is often combined with a polyene such as Amphotericin B. The 
azoles act by binding to the iron ion in cytochrome P-450, which inhibits the 
14 α-demethylation oflanosterol, a step required for ergosterol and cholesterol 
synthesis. The synthetic Allylamines act similarly to the azoles in that they 
inhibit ergosterol synthesis, but they target an enzyme used in the synthesis 
of lanosterol. While these represent many effective topical and systemic 
drugs, the search still continues for safer and more effective antifungal 
agents. 
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1.14. Ketoconazole 
 
1.14.1. Structure and chemistry 
 
 
 
Figure1.20. Chemical structure of Ketoconazole 
 
Ketoconazole is a synthetic azole antifungal agent an imidazole 
derivative (Piscitelli et al, 1991), which contains two nitrogen atoms in the five-
membered azole ring (Cleary, et al., 1992) structurally related to other 
imidazoles e.g. butoconazole, clotrimazole, and econazole. Ketoconazole is 
cis-1-acetyl-4-[4-[[2-(2, 4-dichloro-phenyl) -2- (1H-imidazol-1-ylmethyl)-1, 3-
dioxolan-4-yl] methoxyl] phenyl] piperazine (Cordoba-Diaz et al. 2001). The 
structural formula of ketoconazole is C26H28Cl2N4O4 shown in (Figure 1-20). It 
is a white to slightly beige, odorless powder, soluble in acids, with a molecular 
weight of 531.44 and a melting point of 148 - 1520 C. Assay yields 98% - 
102% (Anhydrous Basis). Ketoconazole as a dibasic compound has pKa of 
2.9 and 6.5. It is almost insoluble in water except at a pH lower than 3 
(Daneshmend, 1981 and Daneshmend, 1990). Ketoconazole available as 
scored white tablets, each containing 200 mg ketoconazole base for oral 
administration. Inactive ingredients are colloidal silicon dioxide, cornstarch, 
lactose, magnesium stearate, microcrystalline cellulose, and povidone. 
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1.14.2. Mechanism of Action 
 
Ketoconazole usually is fungistatic in action, but may be fungicidal at 
high concentrations after prolonged incubation or against very susceptible 
organisms (Sud and Feingold, 1981). 
Like imidazoles, Ketoconazole presumably exerts its antifungal activity 
by altering cellular membranes resulting in increased membrane permeability, 
leakage of essential elements e.g.; amino acids, potassium, and impaired 
uptake of precursor molecules e.g.; purine and pyrimidine precursors to DNA. 
Although the exact mechanism of action of Ketoconazole has not been fully 
determined, it has been suggested that the fungistatic activity of the drug may 
result from interference with ergosterol synthesis, probably via inhibition of C-
14 alpha demethylase, a microsomal cytochrome P-450 dependent enzyme 
system in susceptible fungi, which leads to accumulation of C-14 alpha 
methylated sterols e.g. lanosterol and decrease concentration of ergosterol. It 
appears that this may occur because the nitrogen atom in the drug binds to 
heme iron of cytochrome P-450 demethylase in susceptible fungi (Fabris et al, 
1993, Matthew et al, 1993, Sud and Feinold, 1981 and Borgers, 1983). The 
depletion of ergosterol alters membrane fluidity, thereby reducing the activity 
of membrane-associated enzymes and leading to increased permeability and 
inhibition of cell growth and replication (Van den et al, 1983). 
The fungicidal activity of the drug at high concentrations may result 
from direct physiochemical effect of the drug on the fungal cell membrane. 
In Vitro, Ketoconazole concentration as low as 0.01 µg/ml prevents 
Candida albicans from forming pseudohyphae. This effect enhances 
phagocytosis of the fungi when polymorphonuclear leukocytes are added to 
the cultures because the Leukocytes can phagocytize yeast phase cells more 
easily than mycelial phase cells. 
Further studies are needed to fully elucidate the effect of Ketoconazole 
on steroid synthesis in humans, but the drug apparently directly inhibits 
synthesis of adrenal steroids and testosterone in vitro and in vivo. 
Ketoconazole appears to inhibit steroid synthesis principally by blocking 
several P-450 enzyme systems e.g. 11 β-hydroxylase, C-17, 20-lyase; 
cholesterol side-chain cleavage enzyme. 
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Usual dosages (i.e., 200 – 400 mg daily) of ketoconazole have been 
reported to transiently (for 2 – 12 hours) inhibit testicular testosterone 
synthesis. A compensatory increase in serum luteinizing hormone (LH) 
concentrations may occur. Dosages of 800–1200 mg daily have been 
reported to have a more prolonged effect on testosterone synthesis. In a 
study in males receiving these high dosages, serum testosterone 
concentrations remained at a subnormal level (i.e., less than 300 ng/dL) 
throughout the day in about 30% of those receiving 800 mg daily and in all of 
those receiving 1200 mg daily. Oligospermia, decreased libido, and 
impotence often occurred in these males and azoospermia occurred rarely. 
 
1.14.3. Spectrum 
 
Ketoconazole is active against most fungi, including dermatophytes. 
The drug also has in vitro activity against some gram-positive bacteria, 
including Staphylococcus aureus, Staphylococcus epidermidis, enterococci, 
Nocardia and Actinomadura. 
In vitro, Ketoconazole concentrations of 0.1 - 2 µg/ml generally inhibit 
most susceptible strains of Blastomyces dermatitidis, Coccidioides immitis, 
Cryptococcus neoformans, Epidermophyton floccosum, Histoplasma 
capsulatum, Microsporum canis and Paracoccidioides brasiliensis is generally 
inhibited in vitro by ketoconazole concentrations of 0.002 - 0.1 µg/ml (Borelli 
et al, 1979 and Como and Dismukes, 1994). 
Ketoconazole concentrations of 1 - 25 µg/ml generally are required in 
vitro to inhibit Actinomadura madurae, Aspergillus flavus, Nocardia species, 
petriellidium boydii and Sporothrix schenckii. 
A wide range of ketoconazole MIC values has been reported for 
Candida, MIC90 for Candida albicans, Candida glabrata and Candida tropicalis 
was 0.125 – 16 µg/ml. 
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1.14.4. Determination of ketoconazole in biological fluids 
 
Pharmacokinetics studies and clinical trials of ketoconazole were 
limited due to a lack of readily available methods for quantitation of 
ketoconazole in serum or other biological fluids. 
Several microbiological methods for the analysis of ketoconazole in 
plasma have been described. 
Jorgensen et.al (1981) developed a bioassay for measurement of 
ketoconazole alone or in the presence of therapeutic levels of amphotericin B, 
using an agar diffusion assay incorporating Candida pseudotropicalis. Pairs of 
8 – mm wells cut in the seeded assay medium were filled with four duplicate 
ketoconazole standards and duplicate patient specimens. Zones of inhibition 
were visible after 7 to 8 h of incubation, but were most easily measured after 
overnight growth. The assay allowed determinations of serum ketoconazole 
levels as low as 0.3 µg/ml with a 4.4% coefficient of variation. Thirty-five 
serum samples from patients receiving the drug were assayed by this method, 
and the results were compared with the Coccidioides immitis endospore 
assay. The correlation coefficient between the assays was 0.90. This assay 
was claimed to allow any microbiology laboratory to easily and safely 
determine ketoconazole levels in serum or cerebrospinal fluid. 
Bodet and his coworkers (1986) developed an agar-well diffusion 
bioassay for measurement of flucytosine or ketoconazole using Candida 
pseudotropicalis ATCC 46764 as the assay organism. A test medium 
composed of (per liter) 7 g of Trypticase peptone, 7 g of YNB (yeast-nitrogen 
base), 15 g of glucose, and 15 g of agar was seeded with an inoculum, which 
had been grown to no. 2 McFarland turbidity after 4 to 6 h in YNB-glucose 
broth. Determinations of flucytosine or ketoconazole were performed without 
necessity of heating or diluting of serum samples to alleviate amphotericin B 
interference. A linear relationship between zone diameters and log10 
concentration of the drug was observed over the pharmacologically relevant 
ranges of 25 to 160 µg /ml for flucytosine and 0.5 to 20 µg /ml for 
ketoconazole. The mean coefficient of variability for samples measured on 5 
separate days was 2.4% for flucytosine and 4.0% for ketoconazole. This 
assay represents a significant improvement over previous bioassay methods 
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in that a single test system may be used for measurement of either flucytosine 
or ketoconazole, no serum dilution or pretreatment is required, inoculum 
preparation is accomplished entirely on the day of the assay, and sharp, 
clearly defined zones of inhibition are obtained with both drugs 
The lack of specificity of the microbiological methods has led to the 
development of a number of procedures, which employ high-performance 
liquid chromatography (HPLC) for quantitative determination of ketoconazole 
in biological fluids. 
A rapid and selective HPLC assay was described by Alton in 1980 as 
the first HPLC method for the quantitative determination of ketoconazole in 
human plasma. After extraction of the drug from plasma, the compound is 
separated by HPLC using a reversed-phase column and detected by UV light 
at 205 nm. Quantitation is accomplished by external standardization and the 
determination of peak areas is performed with the aid of an integrating 
computer. The average recovery of ketoconazole over a concentration range 
of 0.1 – 20 µg/ml was 88.2 ± 4.07% S.D. The maximum sensitivity of the 
assay is less than 0.1 µg/ml. The assay is suitable for use in pharmacokinetic 
studies following the administration of therapeutic doses of ketoconazole to 
humans. 
Andrews et.al (1981) developed a reverse-phase, high-pressure liquid 
chromatographic method for the rapid and quantitative determination of 
ketoconazole. Drug levels from 0.5 to 10 µg/ml can be determined in either 
yeast nitrogen base medium or human serum by using an octadecylsilane 
column. A retention time of 4.9 ± 0.1 minutes resulted when the drug was 
eluted from a column with 75% methanol and 25% 0.02 M (pH 7.5) phosphate 
buffer at a flow rate of 2 ml/min. Optimum sensitivity was obtained at a 
wavelength of 231 nm. 
In 1983 another HPLC procedure was described by Pascucci and 
associates for the quantitation of ketoconazole in biological fluids. The 
procedure involves sample preparation using a reverse-phase C18 cartridge 
prior to chromatography and quantitation using peak height ratios (UV 
absorbance detection, 231 nm) of ketoconazole to the internal standard, 
phenothiazine. A sensitivity of 0.2 µg/ml was achieved using a 0.5 ml sample. 
The mean recovery was 86.2%, and overall coefficient of variation of the 
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procedure was 7.1%. This procedure has been used to determine 
ketoconazole levels in human serum, plasma, CSF, and synovial fluid. 
A reversed-phase high-performance liquid chromatographic (HPLC) 
method with terconazole as internal standard was described for the rapid 
analysis of ketoconazole in human serum. Except for diazepam no other drug 
interfered with the analysis. The lowest reproducible limit of the method was 
0.05 mg/l. The coefficient of variation of the procedure was ≤ 7.5% over a 
range of ketoconazole concentrations from 1.0 to 10.0 mg/l and ≤ 16.75% 
over a range from 0.05 to 0.5 mg/l (Turner et al. 1986). 
An accurate and precise procedure for the rapid analysis of 
ketoconazole in the lung, liver, plasma and adrenal gland of the rat has been 
developed by Riley and James (1986). Separation of the drug from 
endogenous substances was achieved by solid-phase extraction followed by 
reversed-phase chromatography on a Novapak C18 column using a mobile 
phase of methanol-acetonitrile-0.02 M phosphate buffer (pH 6.8) (35:30:35). 
Depending on the tissue, the recoveries of ketoconazole and clotrimazole, 
which was used as an internal standard, ranged between 85.0 to 93.6% and 
79.3 to 84.1%, respectively? The reproducibility of the assay was between 3 
and 4%, depending on the tissue involved. The sensitivity of the procedure 
permitted the monitoring of ketoconazole levels for up to 24 h in the adrenal 
and up to 48 h for plasma, lung and liver, following oral administration of 150 
mg/kg of the drug to male rats. 
An HPLC method using fluorescence detection instead of UV detection 
was developed by Yuen and Peh (1998) for the determination of ketoconazole 
in human plasma. The method entailed direct injection of the plasma sample 
after deproteinization using acetonitrile. The mobile phase comprised 0.05 M 
disodium hydrogen orthophosphate and acetonitrile (50:50, v/v) adjusted to 
pH 6. Analysis was run at a flow-rate of 1.5 ml/min with the detector operating 
at an excitation wavelength of 260 nm and an emission wavelength of 375 
nm. The method is specific and sensitive with a quantification limit of 
approximately 60 ng/ml and a detection limit of 40 ng/ml at a signal-to-noise 
ratio of 3:1. Mean absolute recovery value was about 105%, while the within-
day and between-day coefficient of variation and percent error values of the 
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assay method were all less than 14%. The calibration curve was linear over a 
concentration range of 62.5 – 8000 ng/ml. 
Ramos et al. (2000) described three different approaches (methods A, 
B, and C) to attain high-throughput sample preparation and analysis in the 
quantification of ketoconazole in human plasma. Method A consisted of 
acetonitrile precipitation in a 96-well plate, transfer of the supernatant via a 
Tomtec Quadra 96 Model 320, and subsequent injection onto a 50 x 4.6 mm 
(i.d.) Develosil Combi-RP-5 column (packed with C30 bonded silica particles). 
Method B consisted of an identical sample preparation to method A with the 
exception that a Michrom Magic Bullet (trade mark) column, 2.0 - 0.50 mm 
(i.d., tapered bore) x 25 mm length, was used. Lastly, in method C, a 
turbulent-flow chromatography (TurboFlow LC/APCI-MS/MS) module was 
used for the direct analysis of ketoconazole in human plasma. A Sciex API 
3000 was used in methods A and B, while a Micromass Quattro LC was 
employed in method C. Based on the values obtained for the calibrator 
(standard) and quality control samples, all three protocols yielded satisfactory 
accuracy, precision, and reduced manual sample preparation time. 
Khashaba et.al (2000) suggested simple spectrophotometric and 
spectrofluorimetric methods for the determination of clotrimazole, econazole 
nitrate, ketoconazole, miconazole and tolnaftate. The spectrophotometric 
method depends on the interaction between imidazole antifungal drugs as n-
electron donor with the p acceptor 2, 3-dichloro-5, 6-dicyano-1, 4-
benzoquinone (DDQ) in methanol or with p-chloranilic acid (p-CA) in 
acetonitrile. The produced chromogens obey Beer’s law at λmax 460 and 520 
nm in the concentration range 22.5 – 200 and 7.9 – 280 mg/ml for DDQ, and 
p-CA, respectively. The spectrofluorimetric method is based on the 
measurement of the native fluorescence of ketoconazole at 375 nm with 
excitation at 288 nm and or the induced fluorescence after alkaline hydrolysis 
of tolnaftate with 5 M NaOH solution at 420 nm with excitation at 344 nm. 
Fluorescence intensity versus concentration is linear for ketoconazole at 49.7 
– 800 ng/ml while for tolnaftate; it is in the range of 20.4 – 400 ng/ml. The 
proposed methods were applied successfully for the determination of all the 
studied drugs in their pharmaceutical formulations. 
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Farhadi and Maleki (2001) proposed a spectrophotometric method for the 
determination of ketoconazole in pharmaceutical preparations. The method is 
based on the coupled redox-complexation reactions, which proceed in the 
ketoconazole-iron (III) and 1, 10-phenanthroline systems. A linear calibration 
graph was obtained between 1.6 – 16.0 ppm of ketoconazole. The procedure 
was successfully applied for the determination of Ketoconazole in tablet, 
cream and shampoo samples. 
A high-performance liquid chromatographic assay with UV detection 
has been developed for the determination of ketoconazole in human plasma 
(Bruijn et al 2001). Quantitative extraction was achieved by a single solvent 
extraction involving a mixture of acetonitrile-n-butyl chloride (1:4, v/v). 
Ketoconazole and the internal standard (clotrimazole) were separated on a 
column packed with Inertsil ODS-80A material and a mobile phase composed 
of water-acetonitrile-tetrahydrofuran-ammonium hydroxide-triethylamine 
(45:50.2:2.5:0.1:0.1, v/v). The column effluent was monitored at a wavelength 
of 206 nm with a detector range set at 0.5. The calibration graph was linear in 
the range of 20 – 2000 ng/ml, with a lower limit of quantitation of 20.0 ng/ml. 
The extraction recoveries for ketoconazole and clotrimazole in human plasma 
were 93 ± 9.7% and 83 ± 10.0%, respectively. The developed method has 
been successfully applied to a clinical study to examine the pharmacokinetics 
of ketoconazole in a cancer patient. 
A recent HPLC coupled with tandem mass spectrometry (LC–MS–MS) 
has been developed and validated for the determination of ketoconazole in 
human plasma. The method used diethyl ether to extract the ketoconazole 
and the internal standard (I.S.) R51012 from alkalinized plasma sample. The 
LC separation was on a C18 column (50×3 mm, 5 µm) using acetonitrile–
water–formic acid (75:25:1, v/v/v) mobile phase. The retention times were 
approximately 1.8 minute for both ketoconazole and the I.S. The MS–MS 
detection was by monitoring 531.2→82.1 (m/z) for ketoconazole, and 
733.5→460.2 (m/z) for the I.S. The dynamic range was from 20.0 to 10000 
ng/ml based on 0.1 ml plasma, with linear correlation coefficient of ≥ 0.9985. 
The run time was 2.5 minute/injection. The recoveries of ketoconazole and 
the I.S. were 102 and 106%, respectively. The precision and accuracy of the 
control samples were with the relative standard deviations (RSDs) of ≤ 4.4% 
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(n=6) and the relative errors (REs) from −0.6 to 1.4% for intra-day assay, and 
≤ 8.6% RSD (n=18) and −1.4 to 0.9% RE for inter-day assay. The partial 
volume tests demonstrated good dilution integrity. Three freeze–thaw cycles, 
keeping plasma samples at ambient for 24 hours, storing extracted samples 
at ambient for 24 h, and storing frozen plasma samples at approximately −20° 
C for up to 2 months did not show substantial effects (Chen et al, 2002). 
 
1.14.5. Pharmacokinetics 
 
Pharmacokinetics involves the kinetics of drug absorption, distribution, 
and elimination (i.e. excretion and metabolism). The study of pharmacokinetic 
involves both experimental and theoretical approaches. The experimental 
aspect of pharmacokinetics involves the development of biological sampling 
techniques, analytical methods for measurement of drugs and metabolites, 
and procedures that facilitate data collection and manipulation. The 
theoretical aspect of pharmacokinetic involves the development of 
pharmacokinetic models that predict drug disposition after drug 
administration. The application of statistics is an integral part of 
pharmacokinetics studies. Statistical methods are used for pharmacokinetic 
parameters estimation and data interpretation. Statistical methods are applied 
to pharmacokinetic models to determine data error and structural model 
deviations. Mathematics and computer techniques form the theoretical basis 
of many pharmacokinetics methods (Shargel and Andrew, 1999). 
 
1.14.5.1. Pharmacokinetics parameters 
 
a) Elimination rate constant 
The rate of elimination (ke) for most drugs is a first-order process. The 
elimination rate constant, k, is a first-order elimination rate constant with units 
of time–1 (e.g. hr-1). 
 
b) Biological half-life 
The half-life (t½) is the time required for the concentration to become 
equal to one-half of the initial concentration. 
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c) Apparent volume of distribution 
The volume of distribution (Vd) represents a volume that must be 
considered in estimating amount of drug in the body from the concentration of 
drug found in the sampling compartment. The volume of distribution is also 
the apparent volume in which the drug is dissolved. 
 
e) Clearance 
Clearance (Cl) is the measure of drug elimination from the body 
without identifying the mechanism or process. 
 
f) Mean residence time 
The term means residence time (MRT) describes the average time for 
all the drug molecule to reside in the body. MRT may be considered also as 
the mean transit time (Notari et.al, 1975). 
 
1.14.5.2. Bioavailability 
Bioavailability indicates a measurement of the rate and extent (amount) 
of therapeutically active drug that reaches the systemic circulation and is 
available at the site of action (FDA, 2003). 
 
1.14.5.3. Bioavailability parameters 
 
a) Maximum plasma concentration (Cmax) 
The peak plasma drug concentration represents the maximum plasma 
drug concentration obtained after oral administration of drug. Cmax provides 
indications that the drug is sufficiently systemically absorbed to provide a 
therapeutic response. In addition, Cmax provides warning of possibly toxic 
levels of drug. 
 
b) Time to reach Cmax (Tmax) 
The time of peak plasma concentration (Tmax) corresponds to the time 
required to reach maximum drug concentration after drug administration. At 
Tmax peak drug absorption occurs and the rate of drug absorption exactly 
equals the rate of drug elimination. Drug absorption still continues after Tmax is 
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reached, but at slower rate. When comparing drug products, Tmax can be used 
as an approximate indication of drug absorption rate. 
 
c) Area under plasma concentration-time curve (AUC) 
It is the measurement of the extent of drug bioavailability. For many 
drugs the AUC is directly proportional to dose. In some cases the AUC is not 
directly proportional to the administered dose for all dosage levels. These 
types of drugs are described to have non-linear pharmacokinetics behavior 
(Shargel and Andrew, 1999). 
 
1.14.5.4. Methods for assessing bioavailability 
Direct and indirect methods may be used to assess drug bioavailability. 
The design of bioavailability study depends on the objectives of the study, the 
ability to analyze the drug (and metabolites) in biological fluids, the 
pharmacodynamic of the drug substance, the route of drug administration and 
the nature of the drug product. Pharmacokinetic and/or pharmacodynamic 
parameters as well as clinical observations and in vitro studies may be used 
to determine drug bioavailability from a drug product. 
 
a) Absolute bioavailability 
The absolute bioavailability of a given drug from a dosage form is the 
fraction or (percentage) of the administered dose which is absorbed intact into 
the systemic circulation. 
For equivalent doses of administration drug: 
 
Absolute bioavailability = iv
abs
)(AUC
)(AUC
∞
∞
 
 
Where (AUC∞) abs is the total area under the plasma concentration-time 
curve following the administration of a single dose via an absorption site and 
(AUC∞)iv is the total area under the plasma concentration-time curve following 
administration by rapid intravenous injection. 
For non-equivalent doses of administration drug: 
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Absolute bioavailability = absiv
ivabs
D X )(AUC
D X )(AUC
∞
∞
  
 
Where Dabs is the size of the single dose of drug administered via the 
absorption site, and Div is the size of the dose of drug administered as an 
intravenous bolus Injection. 
The absolute bioavailability of a given drug from particular type of 
dosage form may be expressed as a fraction or more commonly, as a 
percentage. 
 
b) Relative bioavailability  
 
In the case of drugs that cannot be administered by intravenous 
bolus injection, the relatives (or comparative) bioavailability is determined 
rather than the absolute bioavailability. In this case the bioavailability of a 
given drug from a “test” dosage form is compared to that of the same drug 
administered in “standard” dosage form, which is either an orally administered 
solution from which the drug is known to be well absorbed or an established 
commercial preparation of proven clinical effectiveness. 
Relative bioavailability  = standard
test
)(AUC
)(AUC
∞
∞
 
 
Where (AUC∞)test and (AUC∞)standard are the total areas under the plasma 
concentration-time curves following the administration of a single dose of the 
test dosage form and of the standard dosage form, respectively. 
When different doses of the test and standard dosage forms are 
administered, a correction for the size of dose is made as follows: 
 
Relative bioavailability = teststandard
standardtest
D X )(AUC
D X )(AUC
∞
∞
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Where Dtest and Dstandard are the sizes of the single doses of the test and 
standard dosage forms, respectively. 
Both absolute bioavailability and relative bioavailability may be 
expressed as a fraction or as a percentage (Shargel and Andrew, 1999). 
 
1.14.5.5. Factors affecting drug absorptions from gastrointestinal tract 
 
Factors that affect drug absorption from gastrointestinal tract include 
gastric emptying, gastrointestinal pH, the environment within the lumen, 
influence of food in the gastrointestinal tract, disease state and physiological 
disorders and the mechanisms of transport of the drugs across the 
gastrointestinal membrane (Aulton, 2002). 
 
1.14.5.6. Pharmaceutical factors affecting drug bioavailability 
 
The formulation factors affecting drug bioavailability can be 
summarized in the following: 
 
a) Disintegration 
 Release of the drug from the dosage form. 
b) Dissolution 
Factors that affect drug dissolution of a solid oral dosage form include 
(a) the physical and chemical nature of active drug substance, (b) the nature 
of the ingredients, and (c) the method of manufacture (Shargel and Andrew, 
1999). 
 
1.14.6. Pharmacokinetics of Ketoconazole 
 
1.14.6.1. Absorption 
 
Ketoconazole is rapidly absorbed from gastrointestinal tract (Fabris et 
al, 1993). In healthy, fasting adults, oral bioavailability of the drug is similar 
following administration of conventional tablets or suspension but is 
somewhat higher following administration of solution (Baxter, 1986). Oral 
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absorption of ketoconazole varies among individuals and bioavailability of 
tablet is 75% (Koch, 1983; Graybill and Drutz, 1980 and Chambers, 2001). 
The bioavailability of oral Ketoconazole depends on the pH of gastric 
contents in the stomach. An increase in the pH results in decrease absorption 
of the drug. 
Concomitant administration of acidic beverages may increase 
bioavailability of oral Ketoconazole in some individuals with achlorhydria. In 
one cross-over study in healthy, fasting adults with achlorhydria (induced by 
administration of 60 mg of oral omeprazole 6–8 hours prior to ketoconazole), 
the peak plasma concentration and area under the plasma concentration-time 
curve (AUC) of the drug averaged 0.8 mcg/mL and 3.46 mcg/mL per hour, 
respectively, when the dose was administered with 240 mL of water and 
averaged 2.44 mcg/mL and 11.22 mcg/mL per hour, respectively, when the 
dose was administered with 240 mL of Coca-Cola Classic (pH 2.5). 
Concomitant administration of drugs, which increase gastric pH, may 
decrease absorption of ketoconazole (Chin, 1995). 
The effect of food on the rate and extent of gastrointestinal tract 
absorption of Ketoconazole has not been clearly determined. However the 
administration of the drug with food increases the extent of absorption and 
results in more consistent plasma concentration of Ketoconazole 
(Daneshmend, 1991) .The food increase absorption by increasing the rate 
and/or extent of dissolution of Ketoconazole e.g.; by increasing bile secretions 
or by delaying stomach emptying. 
In healthy, fasting adults, peak plasma ketoconazole concentrations of 
approximately 4.2, 5, or 6.2 µg/mL occurred 1 – 2 hours following oral 
administration of a single 200 mg dose as tablets, a suspension, or a solution, 
respectively. Mean elimination half-life range from 7.5 – 7.9 hour (Huang et al, 
1986). This dose when given to non fasting in other study, peak plasma 
concentrations of the drug attained within 1 – 4 hours and range form 1.5 – 
4.5 µg/ml; plasma concentrations of the drug were usually less than 0.05 
µg/ml after 24 hours. 
Considerable interindividual variations in peak plasma concentrations 
attained and areas under the concentration–time curves (AUCs) have been 
reported with a specific oral dose of ketoconazole. In one cross-over study in 
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adults who received single oral doses of ketoconazole of 100, 200 and 400 
mg a comparison of dose versus AUC suggested that Ketoconazole 
undergoes saturable first pass elimination since bioavailability of the lower 
dose was relatively poor (Daneshmend, 1981). 
 
1.14.6.2. Distribution 
 
Ketoconazole has been detected in urine, bile, saliva, synovial fluids 
and cerebrospinal fluids following oral administration of a single 200 mg dose 
of the drug in adults (Heel, 1982). Central nerves system penetration of the 
drug is unpredictable and has generally been considered to be minimal. 
In rats, highest concentrations of ketoconazole are attained in the liver, 
pituitary and adrenals; moderate concentrations are attained in the lungs, 
kidneys, bladder, bone marrow, teeth, myocardium and various glandular 
tissues; and lowest concentrations are attained in the brain and testes 
following a single oral dose of the drug (Matthew et al, 1993). It is not known if 
ketoconazole cross the placenta in human; however, the drug crosses the 
placenta in rats. Ketoconazole probably distributes into human milk. 
Ketoconazole is 84 – 99% bound to plasma protein primarily albumin (Fabris 
et al, 1993 and Chambers, 2001), but unbound drug distributes well 
throughout most tissues. Because of their lipophilicity, the concentrations of 
ketoconazole, in urine and cerebrospinal fluid are typically less than 1.0 µg 
per milliliter (Daneshmend and Warnock, 1988). Plasma protein binding of 
ketoconazole was altered in patients with chronic renal and hepatic cirrhosis, 
with the percentage of free ketoconazole markedly increased compared to 
controls (Martinez-Jorda et al, 1990). 
 
1.14.6.3. Elimination 
 
Plasma concentrations of Ketoconazole appear to decline in biphasic 
manner with half-life of approximately 2 hours in the initial phase and 
approximately 8 hours in the terminal phase. A half-life of 1 hour has been 
observed in immunocompromised patients, and a half-life of 11.6 hours has 
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been observed in cancer patients (Daneshmend and Warnock, 1988, 
Badcock et al, 1987). 
Ketoconazole is partially metabolized, in the liver to several inactive 
metabolites by oxidation and degradation of the imidazole and piperazine 
rings, by oxidative O-dealkylation and by aromatic hydroxylation to a large 
number of metabolites, which do not possess antifungal activity 
(Daneshmend, 1981). Urinary excretion of ketoconazole account for only 2 – 
3% (Fabris, 1993). The major route of elimination of ketoconazole and its 
metabolites appears to be excretion into the feces via the bile. The hepatic 
clearance of ketoconazole is saturable such that AUC increases 
disproportionally with increasing dose (Matthew et al, 1993 and Daneshmend 
et al, 1984). 
In one study in fasting adults with normal renal function, approximately 
57% of a single 200 mg oral dose of ketoconazole was excreted in the faces 
within 4 days: 20 – 65% of this was unchanged drug. In the same study, 
approximately 13% of the dose was excreted in urine within 4 days; 2 – 4% of 
this was unchanged drug (Graybill and Drutz, 1980). Ketoconazole is not 
appear to be dialyzable (Brass et al, 1982) 
 
1.14.7. Uses of ketoconazole 
Oral Ketoconazole can be used in the treatment of the following: 
 
1.14.7.1. Blastomycosis 
Blastomycosis caused by Blastomyces dermatitidis, as alternative for 
the treatment of mild to moderate disease. The recommended dose is 200 mg 
once daily and may be increased to 400 mg once daily for serious infections. 
In a multi-center prospective study, high oral doses of 800 mg daily were 
found more effective than lower oral doses of 400 mg daily in the treatment of 
blastomycosis. Success rate after six months of treatment were 100% with 
high doses and 79% with low dose therapy (Anon, 1985). Ketoconazole, at a 
dose of 400 to 800 mg daily, is effective in 70 to 100 percent of patients 
(Como and Dismukes, 1994). For patients who are immunocompromised 
such as transplanted patients or patients with AIDS, treatment with 
amphotericin B followed by long-term treatment with ketoconazole in doses of 
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400 to 800 milligrams daily has been used (Serody, et al., 1993 and Pappas, 
et al., 1992) 
 
1.14.7.2. Candidiasis 
a) Mucocutaneous candidiasis: The recommended dose is 200 mg 
once daily and may be increased to 400 mg once daily if clinical response is 
not sufficient. Recommended treatment duration for candidiasis is one or two 
weeks. The long-term efficacy of oral ketoconazole in thirteen patients with 
chronic mucocutaneous candidiasis has been evaluated (Mobacken and 
Moberg, 1986). In an open noncomparative trial, thirteen patients received 
200 mg ketoconazole once daily for fourteen months. Therapy was continued 
until clinical resolution of symptoms and negative candida culture were 
obtained. On the average, oral lesions resolved after 1 – 2 months, skin 
lesions after two months, finger paronychia after 3 – 4 months and nail lesions 
after 4 – 14 months. Ketoconazole was reported to be effective in treating 
chronic mucocutaneous candidiasis in dose of 100 to 400 mg daily for 3 – 6 
months (Drouhet and Dupont, 1980 and Hay et al, 1980). 
 
b) Oral candidiasis: Ketoconazole 200 – 800 mg daily for 2 – 3 weeks 
has been found useful for treating severe oral or esophageal candidiasis in 
patients with the acquired immunodeficiency syndrome (AIDS) (Fauci et al, 
1984 and Anon, 1991). 
c) Uncomplicated vulvovaginal candidiasis in non-pregnant women: The 
usual dose of Ketoconazole is 200 – 400 mg twice daily for 5 days. (Talbot 
and Spencer, 1983; Kovacs, et al., 1990 and Sobel, 1986). 
 
1.14.7.3. Chromomycosis 
The usual oral dose for adult is 200 – 400 mg. Treatment should be continued 
for a minimum of 6 months (Prod Info Nizoral®, 1995) 
 
1.14.7.4. Coccidioidomycosis 
The availability of the antifungal azoles has changed the outlook for the 
management of coccidioidomycosis, long considered one of the most 
refractory of the systemic mycoses to therapy. Ketoconazole in 200 – 400 mg 
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daily for 2 – 11 months has proven effective in coccidioidomycosis (Graybill et 
al, 1980 and Brass et al, 1980). Twenty-nine patients in an uncontrolled study 
were given 200 mg/day for more than three months before increasing their 
dose. Only 16% of patients responded to 200 mg/day. Seventeen of these 
patients had their dose increased to 400 or 800 mg/day and 71% responded 
to treatment. This data strongly indicates that 200 mg/day is not an adequate 
dose for treating systemic mycosal diseases such as coccidioidomycosis and 
histoplasmosis (Anon, 1982). 
The Medical Literature recommends either ketoconazole or 
amphotericin B as drugs of choice to treat Coccidioidomycosis infections. The 
recommended dose of ketoconazole is 400 mg daily (Anon, 1992). 
 
1.14.7.5. Histoplasmosis 
A low dose of 400 mg/day was found more effective than a higher dose 
of 800 mg/day in patients with localized or disseminated histoplasmosis 
treated for six months or longer, success rate was 100% and 57%, 
respectively. In patients with progressive disease during the first month of 
treatment, the dose increases to 600 or 800 mg/day (Anon, 1985). 
 
1.14.7.6. Paracoccidioidomycosis 
Doses of 200 – 400 mg daily for a period of 2 – 19 months have proven 
effective in paracoccidioidomycosis (Negroni et al, 1980 and Restrepo et al, 
1980). 
 
1.14.7.7. Leishmaniasis 
Ketoconazole doses of 400 – 600 mg daily for 4 – 8 weeks has been 
found useful for treatment of Cutaneous, mucocutaneous or visceral 
leishmaniasis 
 
1.14.7.8. Pityriasis (Tinea) versicolor 
A dose of 200 mg/day for five days is considered effective for most 
cases of Pityriasis versicolor (Hay and Midgeley, 1984). 
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1.14.7.9. Eumycetoma 
A dose was 200- 400 mg daily for periods ranging from three months to 
three years was found to be effective in the treatment of eumycetoma caused 
by Madurella mycetomatis. (Mahgoub and Gumaa, 1984). 
 
1.14.7.10. Transplantation 
A Ketoconazole dose of 82 mg/day is required for reduce cyclosporine 
dose by 73% at twelve moths and 70% at fifty-four months of concurrent use 
of ketoconazole and cyclosporine in kidney transplant recipients (Sobh et al, 
2001). 
 
1.14.7.11. Renal failure 
Dose reduction is not required, since very little active drug is excreted 
via the kidneys (Graybill and Drutz, 1980). 
 
1.14.7.12. Hepatic insufficiency 
Ketoconazole is extensively metabolized in the liver. However, specific 
dosing adjustments have not been described (Graybill and Drutz, 1980). Dose 
reductions should be considered in patients with severe liver disease. 
 
1.14.8. Adverse effects of Ketoconazole 
As ketoconazole is one of azole compounds, a number of side effects 
are associated with ketoconazole as a result of inhibition of mammalian 
enzymes (Venkatakrishnan, 2000). 
 
a) Gastrointestinal tract effects: The most frequent adverse effects of 
ketoconazole are nausea and/or vomiting which have been reported in 
3 - 10% of patients receiving 400 mg/day but increase to more than 
50% in patients receiving more than 800 mg/day (Chambers, 2001 and 
Sugar, et al., 1987). Abdominal pain, a diverse gastrointestinal tract 
effect, appears to be dose related. These side effects are reported less 
frequently when ketoconazole is administered with food, and usually 
subside with continued therapy with the drug. 
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b) Hepatic effects: Ketoconazole leads to liver damage due to its ability 
to inhibit cytochrome P450 3A4, the major P450 isoform of the liver 
(Suzuki, 2000). The inhibition of P450 3A4 results in drug-drug 
interactions involving ketoconazole and a decrease in the rate of 
clearance of many drugs (Tsunoda, 1999). Steroid biosynthesis by 
P450 enzymes is also inhibited by ketoconazole, presumably due to 
the binding of ketoconazole to the mitochondria of P450 enzymes, the 
drug causes transient increase in serum AST (SGOT) and ALT 
(SGPT). Ketoconazole induced hepatotoxicity usually is reversible 
following discontinuance of the drug. 
 
c) Endocrine effects: administration of low doses of ketoconazole leads 
to a significant reduction in serum androgen levels (Sikka, 1985). 
Bilateral gynecomastia with breast tenderness has occurred in some 
men during therapy with Ketoconazole. 
 
d) Other Adverse effects: Pruritus in about 2%, Rash, dermatitis and 
purpura, headache, dizziness, arthralgia, fever and Chills (Chambers, 
2001). 
 
1.14.9. Precautions and contraindications 
 
Ketoconazole has been associated with hepatotoxicity, which rarely 
results in death. 
Patients receiving the drug should be closely monitored clinically and 
biochemically. Liver function tests, including alkaline phosphatase, GGT, 
GGTP and bilirubin, should be performed prior to initiation of Ketoconazole 
therapy and frequently (e.g.; biweekly during the first two months of therapy 
and monthly or bimonthly thereafter) during therapy, particularly in patients 
receiving prolonged therapy or other potentially hepatotoxic drugs In patients 
with a history of hepatic disease the possibility that Ketoconazole may 
depress adrenocortical function should be considered. 
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Ketoconazole is contraindicated in patients with Known hypersensitivity 
to the drug. Concomitant administration of Ketoconazole and terfenadine or 
astemizole is contraindicated (Prod Info Nizoral®, 1998). 
 
1.14.10. Mutagenicity and carcinogenicity 
 
There was no evidence of Ketoconazole–induced carcinogenicity or 
mutagenicity in long term study in mice and rats. Its use during pregnancy is 
not recommended, and because of secretion of the drug into breast milk, its 
use in nursing mothers also is unwise (Chambers, 2001). 
 
1.14.11. Drug interactions 
 
• Concomitant administration of drugs, which decrease gastric acid 
output or increase gastric pH, may decrease absorption of the 
antifungal agent. (Brass, et al., 1982 and Carison, et al., 1983). 
• Concomitant administration of Ketoconazole and rifampin has resulted 
in decrease serum concentrations of Ketoconazole. 
• Norfloxacin may enhance the antifungal activity of antifungal agents. 
• Concomitant administration of Ketoconazole and cisapride is 
contraindicated also with terfenadine and astemizole . 
• Like other imidazole derivatives Ketoconazole may enhance the 
anticoagulant effect of cumarin drugs (Brass et al. 1982). 
• Concomitant administration of Ketoconazole with cyclosporine, 
tacrolimus, corticosteroids and midazolam may result in increased 
plasma concentration of this drug (Abraham et al.2003). However, 
ketoconazole is less expensive than fluconazole and itraconazole, an 
especially important consideration for patients receiving long-term 
therapy. 
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1.15. Clinical Studies 
 
The pharmacology of ketoconazole in patients with fungal infections 
after the administration of 50, 100, and 200 mg doses of ketoconazole was 
studied by Brass et al. (1982). They observed that there was a linear increase 
in the area under the serum concentrations curve; which was not apparent 
when higher doses of ketoconazole were given. An increase in the area under 
the curve occurred in patients receiving 200 mg daily who were restudied after 
1 to 12 months of therapy. However, normalized area under the curve 
appeared to decrease after higher doses were administered chronically. The 
half life ranged from 2.0 to 3.3 hours. Peak serum concentrations up to 50 
µg/ml were detected in this study, and potentially therapeutic concentrations 
were detectable up to 26 hours after high doses. Ketoconazole penetrated the 
saliva and inflamed joint fluid and meninges, although variably, and could be 
demonstrated in some other tissue compartments. In the presence of renal 
failure, ketoconazole disposition was not altered, whereas in the presence of 
hepatic insufficiency, an alteration in disposition was suggested. The 
interactions of ketoconazole and other drugs were studied. Of note, antacids 
did not significantly affect ketoconazole pharmacokinetics (nor did meals), and 
ketoconazole and warfarin did not appear to affect the pharmacokinetics of 
the other. 
Single oral doses of ketoconazole, 200 mg or miconazole, 250 mg 
were given in a randomized cross-over study to 10 healthy volunteers. 
Ketoconazole was administered (i) after fasting (both brand 1 [Orion 
Pharmaceutical Co.] and brand 2 [Janssen Pharmaceutical] were tested), (ii) 
after a standardized meal (660 Kilocalories; 2,772 kJ) (brand 1), and (iii) with 
300 ml of orange juice (pH 3.8) (brand 1). Miconazole was administered after 
fasting. Venous blood samples for HPLC determinations of ketoconazole and 
gas chromatographic (GC) analyses of miconazole were drawn periodically up 
to 24 hours. The concentrations of ketoconazole in sera attained with the two 
brands were not statistically different. The peak concentrations of 
ketoconazole attained with brand 1 were 4.1 ± 0.3 µg/ml (mean ± standard 
error of the mean) after fasting, 2.3 ± 0.3 µg/ml after the standardized meal (P 
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< 0.01), and 3.6 ± 0.2 µg/ml with orange juice. The peak concentrations were 
reached in 1.4, 2.3 (P < 0.05), and 1.8 hours, respectively, whereas the areas 
under the serum concentration-time curves were 14.4 ± 2.21, 8.6 ± 1.33 (P < 
0.05), and 13.4 ± 1.30 µg.h/ml, respectively. The half-lives (1.7 to 2 hours) did 
not vary significantly among the different regimens. Compared with 
ketoconazole, oral absorption of miconazole was poor (peak concentration, 
0.47 ± 0.7 µg/ml; time to reach the peak concentration, 2.6 hours; area under 
the serum concentration-time curve, 1.10 ± 0.20 µg.h/ml) (Mannisto, 1982). 
In a study involving patients with advanced malignancies, twenty-seven 
volunteers were given 200 mg of ketoconazole orally every 6 or 12 hours. 
Blood samples were collected during these intervals and after the last dose to 
determine plasma concentrations and half-lives (Maksymiuk, 1982). The 
mean plasma concentrations measured after the initial dose were 1.7 ± 1.1 
µg/ml at 2 hours, 0.9 ± 0.2 µg/ml at 6 hours, and 0.7 ± 0.4, µg/ml at 8 hours. 
Plasma concentrations rose significantly in patients on the every-6-hours 
schedule. Concentrations were more variable in patients on the every-12-
hours schedule, and changes in mean plasma concentrations after 7 and 14 
days were not significant. Half-lives ranged from 1.3 to 11.6 hours in individual 
patients. The mean half-life for all patients studied was 3.7 ± 0.6 hours on day 
1. The calculated area under the curve was 12.0 ± 4.7, µg.h/ml on day 1; it 
increased after 7 and 14 days of administration (every-6-hours schedule), 
suggesting plasma binding or wide drug distribution or both. Saturation of 
storage compartments is also suggested. Less than 1% of the administered 
dose was recoverable active drug from the urine over 6 hours. 
Daneshmend and his coworkers (1983) investigated the 
pharmacokinetics of Ketoconazole in healthy subjects. Ketoconazole 200 mg 
was given twice daily for five days to eight subjects. The serum 
pharmacokinetics was examined with the first dose on day 1 and with the 
ninth dose on day 5. The serum half-life of ketoconazole was 74.8 ± 13.9 
minutes (mean ± S.D.) on day 1, and 155.9 ± 32.7 minutes on day 5. On day 
1 the area under the serum concentration time curve was 626.9 ± 230.1 
mg/l.min, and 1441 ± 897.3 mg/l.min on day 5. Antipyrine kinetics was 
determined before and after the course of ketoconazole. There was no 
significant change in the clearance and half-life of antipyrine. Ketoconazole in 
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the doses used in this study does not appear to alter hepatic microsomal 
enzyme activity in man. The increased ketoconazole half-life and area under 
the serum concentration-time curve on day 5 were in part caused by food. 
Other mechanisms for these changes such as saturation of a tissue 
compartment or a change in the elimination of ketoconazole during chronic 
dosing may also be responsible. 
Delivery of ketoconazole to human stratum corneum was studied by 
Harris associates (1983). Thirteen healthy volunteers, three patients with 
chronic fungal disease and one patient with palmar-plantar hyperhidrosis were 
given 400 mg of ketoconazole daily for various lengths of time. The 
ketoconazole content of palmar stratum corneum, eccrine sweat, sebum, and 
serum was measured by HPLC (sensitivity, 0.005 to 0.010 µg/ml). Palmar 
stratum corneum obtained after 7 and 14 days of daily administration 
contained up to 14 µg of ketoconazole per g. Ketoconazole was not found in 
sebum after 7 or 14 days of daily ingestion of the antimycotic agent. Sebum 
from three patients with chronic fungal infection treated for > 9 months 
contained ketoconazole (x, 4.7 pg/g). Thermogenic whole body eccrine sweat 
contained a mean of 0.059 pg/ml on day 7 and 0.084 pg/ml on day 14 of daily 
administration. Ketoconazole appeared in Thermogenic whole body eccrine 
sweat and palmar hyperhidrotic sweat within 1 hour after a single oral dose. 
Partition studies of ketoconazole containing eccrine sweat demonstrated a 10-
fold greater concentration in the sediment phase (desquamated keratinocytes) 
compared with the clear supernatant phase. In vitro studies with [3H] 
ketoconazole-supplemented supernatant sweat revealed preferential binding 
to stratum corneum, hair, and nails and its partitioning to lipid-rich sebum. The 
study concluded that eccrine sweat rapidly transports ketoconazole across the 
blood-skin barrier, where it may bind or partition to keratinocytes and surface 
lipids. 
Daneshmend and his coworkers (1984) studied the Influence of Food 
on the pharmacokinetics of Ketoconazole. Eight healthy adults were given 
single oral doses of ketoconazole (200, 400, 600, and 800 mg) in the fasting 
State and with a standard breakfast at weekly intervals according to a 
balanced block design. Concentrations in serum were measured up to 32 h 
after the dose. Food did not reduce ketoconazole absorption or significantly 
 55
alter peak ketoconazole concentrations in serum, though there was a food-
related delay in achieving peak concentrations. At the 400 and 600 mg doses, 
food appeared to enhance absorption, but this effect was not seen at the 800 
mg dose. With an increase in dose, the half-life and area under the serum 
concentration-time curve increased disproportionately, suggesting that the 
pharmacokinetics of ketoconazole may be dose dependent. Up to the 800 mg 
dose, the elimination of ketoconazole did not appear to be saturable. 
Administration of the drug with food is unlikely to be a cause of therapeutic 
failure. 
It has been emphasized that Ketoconazole inhibits adrenal 
steroidogenesis in normal subjects during short term treatment. Since this 
drug is used in the long term prophylaxis of fungal infections in patients with 
hematological malignancies, Dandona and associates (1985) have 
investigated whether such patients have evidence of adrenocortical 
suppression. Six patients on long term prophylaxis with ketoconazole were 
given tetracosactrin stimulation tests. All patients had high basal cortisol 
concentrations, which increased further after administration of 25 IU of 
tetracosactrin. It is concluded that leukaemic patients receiving long term 
Ketoconazole treatment do not have adrenocortical suppression. They may, in 
fact, have hyperstimulated adrenocortical function due to stress and 
hypovolemia. 
The pharmacokinetics and bioavailability of ketoconazole given as a 
200 mg single dose in a tablet, suspension, or solution were studied in 24 
fasting healthy males by using a crossover design (Huang et al, 1986). Levels 
of ketoconazole in plasma were determined for up to 48 hours by a sensitive 
reverse-phase HPLC method. The absorption of ketoconazole was rapid, with 
mean maximum concentrations of the drug in plasma of 4.2, 5.0, and 6.2 
µg/ml attained at 1.7, 1.2, and 1.0 hours, respectively, after administration of 
the tablet, suspension, and solution, respectively. The mean distribution and 
elimination half-life values were 1.5 to 1.7 and 7.5 to 7.9 h, respectively. The 
mean oral clearance of the solution dose was 209 (± 82.9 standard deviation) 
ml/min, and the mean apparent volume of distribution was 88.31 (± 68.72) 
liters. The relative bioavailabilities for the tablet and suspension were 81.2 (± 
33.5) and 89.0 (± 23.1)%, respectively, of that of the solution. The data 
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indicated the bioequivalence of the tablet to the suspension and of the 
suspension to the solution. Dose proportionality of ketoconazole was also 
studied in 12 volunteers after they received solution doses of 200, 400, and 
800 mg. Linear correlations between the dose and the maximum 
concentration of the drug in plasma, the time to the maximum concentration, 
and the area under the concentration-time curve were observed. However, 
the increase in the area under the curve was more than proportional to the 
dose given. The levels in plasma seemed to decay at a lower rate after 400 
and 800 mg doses. The mean oral clearance decreased from 244.9 to 123.6 
and 80.0 ml/min, respectively, as the dose increased from 200 to 400 and 800 
mg. The apparent dose-dependent kinetics may have been due to the 
presystemic elimination and capacity-limited hepatic metabolism, which 
become saturated at higher doses. 
Ketoconazole pharmacokinetics were determined in nine adults with 
hematological malignancy after one week on a 200 mg daily dose and later 
after one week on a 400 mg daily dose. The area under the serum 
concentration-time curve (AUC) reached 12.3 ± 7.7 mg/l.h (mean ± S.D.) on 
the 200 mg dose and increased to 23.0 ± 18.2 mg/l.h on the 400 mg dose (p < 
0.05). The half-life of ketoconazole was 3.1 ± 1.9 h on the 200 mg dose and 
3.5 ± 1.7 h on the 400 mg dose. Peak concentrations were 3.2 ± 1.8 mg/l and 
4.6 ± 3.2 mg/l on the 200 mg and 400 mg doses, respectively. Trough 
ketoconazole concentrations were undetectable 24 hours after either dose. 
There was no correlation between the leukocyte count and any 
pharmacokinetic parameter for ketoconazole. Variation in AUC was 20-fold on 
the 200 mg daily dose and 8-fold on the 400 mg per day regimen. 
Measurement of serum levels during ketoconazole treatment appears 
necessary in view of the unpredictable concentrations achieved. Once-a-day 
dosage regimens of Ketoconazole in immunocompromised patients may be 
inappropriate. The investigators recommended that future clinical trials should 
adopt a two or three times a day dosing regimen, as this may confer a 
pharmacokinetic and therapeutic advantage (Stockley et al., 1986). 
Biliary excretion, and pharmacokinetics of ketoconazole in Sprague-
Dawley rats were determined after intravenous administration (Remmel, 
1987). Greater than 80% of the radioactivity after a 5 mg/kg IV dose of 3H-
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ketoconazole was excreted in the feces. Urinary excretion was essentially 
complete after 48 hours; however, fecal excretion was prolonged over a 7-day 
period. Biliary excretion of radioactivity averaged 54.3 ± 18.0% of the dose 
over a 7.5 – 8 hour period in pentobarbital-anesthesized rats. The possibility 
of enterohepatic recirculation was examined using a linked rat technique. 
Less than 2% of the radioactivity was found in the recipient bile over 9 – 12 h. 
In eight male rats, the plasma pharmacokinetics of ketoconazole, as 
determined by an HPLC assay with fluorescence detection, were as follows: 
Vd = 655 ± 91 ml/kg, Cl = 14.4 ± 5.1 ml/min/kg, and t1/2 = 35.0 ± 12.3 min. 
Three of the rats were given an additional oral dose to determine absolute 
bioavailability. The time to peak was 30 – 60 min, and the bioavailability was 
35.8 ± 3.55%. Previous studies have indicated that ketoconazole is well 
absorbed in rats; therefore, the poor bioavailability is probably due to first 
pass metabolism. The prolonged fecal excretion of radioactivity from an 
intravenous dose was probably caused by slow elimination of ketoconazole 
metabolites. 
Badcock et al (1987) have studied the pharmacokinetics of 
ketoconazole in seven patients who took it for 1 – 6 months at a dose of 200 
mg daily. The mean elimination half-life of the drug was 3.3 h, and although 
the ketoconazole was given only once daily, a satisfactory clinical response 
was obtained in all seven individuals. Only a small fraction of the absorbed 
drug (mean 0.22%) was excreted unchanged in the urine, suggesting almost 
complete metabolism. The results support the concept that anti-mycotic 
activity in the tissues continues after the plasma drug concentration has fallen 
below a critical level. The results also support the concept of a change in 
pharmacokinetics with chronic dosing. Ketoconazole, an imidazole-piperazine 
compound, is an orally active antimycotic agent. In addition, ketoconazole is a 
specific inhibitor of cytochrome P450 3A4. As about 60% of oxidized drugs 
are biotransformed by this isoform, the potential effect of a concomitant 
administration of ketoconazole on drug disposition may be of interest during 
drug development. 
One hundred and sixty patients were entered in two multicenter 
protocols to receive 400 to 2,000 mg of ketoconazole once daily for 
nonmeningeal or meningeal coccidioidomycosis (Sugar et. al., 1987). For 24 
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hours after administration of all doses, mean concentrations in serum 
exceeded MICs for Coccidioides immitis (trough concentrations, > 1 µg/ml). 
Mean peak concentrations occurred 4 to 6 h after administration, ranging from 
7 to 17 µg/ml for doses of 400 to 2,000 mg. Incremental increases in peak 
concentrations in serum were greatest at doses of 1,200 mg. 
To investigate whether long-term therapy altered concentrations in 
serum, serial data were studied by several methods. The results suggested a 
trend to increased levels in serum with prolonged therapy, but were not 
statistically significant. All 168 cerebrospinal fluid (CSF) samples from 
meningitis patients contained <2.9 µg/ml and only 6 contained > 1 µg/ml. 
There was no apparent relation between dose, time after dose, site of CSF 
sampling, or concurrent inflammation and CSF ketoconazole concentration. 
Neither concentration in serum, toxicity, nor outcome correlated with dose, 
calculated in milligrams per kilogram at the fixed doses (400-mg increments) 
under study. Likewise, at the various doses, concentration in serum did not 
correlate with outcome or toxicity, suggesting that individual drug disposition 
was not an important factor in outcome or toxicity. Toxicity was reversible, and 
principal side effects were nausea and vomiting (50%), gynecomastia (21%), 
decreased libido (13%), alopecia (8%), elevated liver function tests (5%), 
pruritus (5%), and rash (4%). Gastrointestinal and endocrinologic toxicity were 
dose related and increased at doses >800 mg. The cumulative percent toxicity 
requiring discontinuation of drug was 6, 17, 23, and 56% at 400, 800, 1,200, 
and 1,600 mg doses. Doses of > 400 mg are thus markedly more toxic, and 
efficacy data for nonmeningeal disease have not demonstrated that they are 
more efficacious. 
Stephen and his coworkers (1991) compared the effects of 
concomitant sucralfate administration with ranitidine administration on the 
disposition of a 400 mg ketoconazole. Six healthy male volunteers were 
randomized to receive 400 mg of ketoconazole alone, 1.0 g of sucralfate 
concomitantly with a 400 mg ketoconazole dose, or ranitidine, administered 2 
hours prior to a 400 mg ketoconazole dose to titrate to a gastric pH of 6. All 
subjects received all three regimens in crossover fashion. Gastric pH was 
measured continuously for 4 hours after ketoconazole administration in all 
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subjects by using a Heidelberg radiotelemetry pH capsule. Relative 
ketoconazole bioavailability was compared between treatments. With 
sucralfate, five of six subjects demonstrated a decrease in the peak drug 
concentration in serum as well as an increase in the time to peak 
concentration, indicating a delay in ketoconazole absorption. The mean area 
under the concentration-time curve from 0 to 12 h for ketoconazole following 
gastric alkalinization was significantly different from that of either 
ketoconazole alone or ketoconazole with sucralfate (P < 0.01). Continuous 
gastric pH monitoring allowed correlation between the decrease in 
ketoconazole bioavailability observed with ranitidine and the increase in 
gastric pH. The apparent decrease in ketoconazole bioavailability observed 
with sucralfate appears to be caused by an alternative mechanism since a 
change in gastric pH was not observed. On the basis of these findings, 
separating the administration of ketoconazole and sucralfate should be 
considered to decrease the potential for interaction of sucralfate on 
ketoconazole bioavailability. 
The disposition of ketoconazole was characterized in the rat over a 
wide dose/concentration range (Matthew, 1993). Bolus dose (0.03 – 10 
mg/kg) studies indicate that plasma concentration-time profiles for 
ketoconazole are not superimposable when dose normalized because of 
nonlinearities occurring in both volume of distribution and clearance. The 
volume of distribution decreases from 3 to less than 1 L/kg, while the plasma 
clearance decreases 10-fold from 25 mL/min/kg as the dose is escalated. 
From these results, infusion rates were calculated to maintain the plasma 
concentrations achieved with particular bolus doses. The curvilinear 
relationship between steady-state plasma concentration (0.015 – 8.3 mg/L) 
and ketoconazole infusion rate (0.021 – 2.45 mg/hr/kg) was analyzed in terms 
of Michaelis-Menten kinetics. A Vmax of 3.2 mg/hr/kg and Km of 2.1 mg/L were 
obtained by nonlinear regression analysis. At the end of the ketoconazole 
infusion, liver, adrenals and kidneys were removed and assayed for 
ketoconazole. Tissue-to-plasma partition coefficients for the liver and adrenals 
showed a marked dependence upon steady-state plasma concentration. Both 
parameters (liver, 22; and adrenals, 53) showed a decrease of approximately 
10-fold as the plasma concentrations were increased. In contrast, the kidney: 
 60
plasma partition coefficient (1.8), blood: plasma concentration ratio (0.6), and 
plasma binding (96%) of ketoconazole did not show a concentration 
dependence over the range studied. It is concluded that the liver is an 
important determinant of ketoconazole's volume of distribution and that 
saturation of this process accounts largely for the reduction in volume of 
distribution with increasing dose. 
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1.16. Aims and Objectives 
 
Aims 
To comparison of two dosing regimens of Ketoconazole in patients with 
Eumycetoma. 
 
Objectives 
 
a) To determine the pharmacokinetic parameters of 400 mg ketoconazole 
given twice daily. 
b) To determine the pharmacokinetic parameters of 800 mg ketoconazole 
administered twice daily. 
c) To compare between the two dosing regimen. 
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2. Experimental 
2.1. Subject and Study site 
 
The study was carried out in the Mycetoma research center, Suba 
Teaching Hospital, Khartoum Sudan. 
Twelve patient adults (males and females) were included in this study. 
The patients were selected from those who attended Suba hospital out patient 
clinic and were seen by clinician there. The patients’ selection criteria included 
confirmed eumycetoma caused by Madurella mycetomatis and compliance 
with follow-up. None of the selected patients take alcohol or smoke cigarettes. 
No abnormalities were found according to the physical tests and laboratory 
examinations. The patients were screened to assure that they did not take 
previous mycetoma treatment prior the trials or any other medication during 
the trial unless consulting the investigators. Drug that are contraindicated with 
Ketoconazole, serious concomitant diseases, life expectancy less than 3 
month, age less than 18 years are considered as exclusion criteria. Each 
patient was given a full explanation of the purpose of the study, procedures, 
duration, discomfort, benefits, confidentiality and the extent to which it is 
maintained. His/her approval was recorded in a written consent form. The 
proposal for the study was reviewed and approved by the Ethics Committee of 
the National Health Laboratory, Khartoum, Sudan. 
 
2.2. Study design and treatment schedule 
 
A comparative open randomized investigation was carried out in two 
groups of patients. Each group was treated with a different dosing regimen of 
ketoconazole. Formulations used and treatment schedule are shown in table 
2.1. 
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2.3. Clinical trials 
 
Tow different regimens were used in the study; ten patients were 
included for each regimen. Only six patient of each regimen completed the 
study. The two regimens were oral ketoconazole 200 or 400 mg given twice 
daily (i.e. 400 or 800 mg per day) for three months. After that the response 
was evaluated and if there were clinical improvement, treatment with 
ketoconazole was continued for a total of six month. If no improvement had 
occurred, the patients were treated by the attending physician with a suitable 
regimen. 
 
Table 2.1. Ketoconazole formulation and doses 
 
Group Formulation strength Initial Dose Subsequent doses 
(for 6 months) 
A Ketoconazole tablets, 200 mg 2 tablets 1 tablet BD 
B Ketoconazole tablets, 200 mg 4 tablet 2 tablets BD 
 
 Each patient took a single dose equivalent to 400 or 800 mg 
ketoconazole on the first day and the same dose was divided into two doses 
twelve hours apart on subsequent days for six months. The dose was 
administered on a full stomach following a standard breakfast, with 250 ml of 
drinking water. Uniformity of meals was ensured throughout of the trials. No 
drugs were taken during the trial period. Blood samples (3 ml) were collected 
at base line 0, and at 1, 2, 3, 4, 6, 8, 12, 16, 20, 24 hours following 
ketoconazole administration on the first day. Addition blood samples (two 
samples) were collected on weeks 2, 3, 4 and months 2, 3, 4, 5 and 6. One 
sample immediately before drugs administration and the other sample at 2 
hours after drugs administration, in last month; following the last dose 
administration, the first day sampling schedule was repeated. 
The blood samples were collected in heparinized test tubes and 
centrifuged at 4000 rpm for 10 minutes and the plasma was separated and 
transferred by master pipettes to Ependorff tubes and kept in deep freezing at 
– 20 °C until analysis. 
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Assessment of patients was carried at entry, weekly for one month, monthly 
for six months, and at end of the Ketoconazole treatment. 
 
The assessment procedure was as follows: 
 
? Personal data 
? Name:                                                                   .Age:           Sex: 
? Occupation:                             Residence:                              wt: 
 
? Medical history: 
 
? Physical examination: 
 
? Local examination: 
? Skin appearance: 
? Number of discharging sinuses: 
? Degree of disability: 
? Degree of pain: 
? Measurement of lesion circumference: 
 
? Recommended Investigation: 
? Ultrasound: 
? X-ray: 
? Biopsy: 
? Culture: 
 
? Laboratory assessments: 
? Full blood count: 
? Liver enzymes: 
? Serology: 
 
Efficacy parameters: 
 
Skin Colour  
? 0 normal color  
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? 1 abnormal color 
 
Skin attachment: 
? 0 normal mobile skin  
? 1 mildly fixed to underlying tissue 
? 2 severe disability 
 
Number of discharging sinuses                            number 
? Degree of disability  
? 1 mild disability  
? 2 moderate disability  
? 3 severe disability  
 
Measurement of swelling:                                         cm 
Radiological finding 
? 0 no lesions  
? 1 mild bone involvement  
? 2 moderate bone involvement  
? 3 severe bone involvement  
  
Ultrasound of lesions: 
? 0 no grains  
? 1 grains present  
? 2 tissue reaction 
  
Culture of biopsy  
?  0 negative  
? 1 positive  
 
Serology: 
?  0 negative 
? 1 positive  
? 1 positive, high intensity  
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Clinical evaluation 
?  Complete response                    cured with relapse  
? Partial response                         < 50 % of sinuses are healed and  
                                                             < 50 % decrease of the swelling  
? Stable disease:                              non of other descriptions 
? Progressive disease                     increasing lesions 
 
Relapse after initial response at day 30 and during follow–up 
 
Evaluation of serology  
? No change 
? Decrease in number of precipitation lines 
? Became negative  
Histological Evaluation  
? Failure                  no decrease in number of grain  
? Improved             decrease number of grain  
? Success               absence of grain  
? Relapse                new grains after initial decrease in no  
 
Microbiological Evaluation  
? Failure                positive culture  
? Success              negative culture  
? Relapse               positive culture after earlier success cure  
 
Data Recording 
• Data entered on a Patient Record Form. 
• Data processed and analyzed. 
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2.4. Materials and methods 
 
2.4.1. Determination of ketoconazole in plasma  
 
 Several analytical procedures have been developed for measurement 
of ketoconazole concentration in biological fluids. Due to its high selectivity, 
good sensitivity and reproducibility, the HPLC method was used by several 
researchers as the method of choice for the determination of ketoconazole in 
biological fluids of both man and animals. The first HPLC method for the 
determination of ketoconazole in plasma was described by Alton (1980); this 
method involved lengthy multiple extractions and did not employ internal 
standards. Subsequently, Pascucci et al. (1983) described a simplified sample 
preparation technique employing C18 reversed- phase cartridges and 
phenothiazine as an internal standard. Riley and James (1986) found direct 
procedure to be applicable to the analysis of ketoconazole in the lung, liver 
and adrenal of the rat and alternative strategies are presented in their study. 
Turner et al. (1986); Yuen and Peh (1998); Ramos et al. (2000); Khashaba et 
al. (2000), Bruijn et al. (2001), Farhadi and Maleki, (2001) and Chen et al. 
(2002), all used the HPLC technique for the determination of ketoconazole 
levels in different studies. Therefore in present study the plasma 
concentrations of ketoconazole were measured by HPLC.  
 
2.4.2. Materials 
 
 All solvents were HPLC grade and the chemicals were analytical 
grade. Ketoconazole was a gift from Pharmaline Pharmaceutical (Lebanon).  
 
2.4.3 Instrumentation and chromatographic system 
 
A high performance liquid chromatographic (HPLC) method for the 
determination of ketoconazole in human plasma using fluorescence detector 
is described. 
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The drug was extracted from 200 µl of plasma with 7 ml t-butylmethylether. 
The extract was evaporated at 45°C and the residue was reconstituted with 
300 µl of mobile phase and injected into the HPLC system (20 µl). 
The drug and the internal standard (Itraconazole) were eluted from 
Symmetry C8 column (3.9*150 mm, 5µm) at 30 °C with a mobile phase 
consisting of (de-ionized water-acetonitrile-methanol (40:50:20% v/v/v) and 
1ml triethylamine, then adjusted to pH 7.0 using 30% glacial acetic acid, at 
flow rate of 2.0 ml/min. The separation was monitored using a fluorescence 
detector at λex 250 nm and λem 370 nm. 
 
2.5. Data analysis 
 Quantitation was achieved by measurement of the peak area ratio of 
the drug to the internal standard following validation of the HPLC procedure. 
The peak area ratios of drug/internal standard were plotted against the 
concentrations. The slope, intercept and correlation coefficient were 
determined by weighted (1/χ) linear least squares regression. 
The analysis is based on measuring the concentration of ketoconazole 
in plasma. The area under the plasma concentration-time curve between 0 
and 24 hr (AUC0→24) was calculated by trapezoidal rule and the AUC to infinity 
( AUC0→∞ ) was estimated from the slope of the declined phase and the last 
measured concentration. The maximum drug concentrations in the plasma 
(Cmax) and the time when it was reached (Tmax) were obtained directly from 
plasma concentration versus time data. The AUC0→∞ of ketoconazole together 
with Cmax and Tmax were used to describe the extent and rate of its 
bioavailability, respectively. 
 A non-compartmental model using simple Excel® Software package 
was employed for calculation of pharmacokinetic parameters. The elimination 
rate constant (Ke) and half- life of elimination (T½) were calculated by linear 
regression of terminal slope of excretion rate profiles. The AUC0→24 hr was 
calculated by trapezoidal rule and the AUC0→∞ was obtained by adding the 
Cfinal/ke to AUC0→24 hr, where the Cfinal is the last measurable concentration. 
The mean residence time (MRT0→∞) was obtained by calculating the ratio of 
the area under the first moment curve for 0 to infinity (AUMC0→∞) by AUC0→∞. 
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2.6. Statistical analysis 
 
 The computer program Excel was used for statistical analysis. All 
parameters were expressed as (Mean ± SD). The coefficient of variation (C.V) 
was calculated for the pharmacokinetic parameters. 
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3. Results 
3.1. Analytical procedure 
A high performance liquid chromatographic method (HPLC) for the 
determination of ketoconazole in human plasma using fluorescence detection 
was used. The HPLC analytical method exhibited good reproducibility and 
selectivity. It permitted simultaneous determination of ketoconazole and 
itraconazole (internal standard) in small amounts in plasma with no 
interference from metabolites or endogenous materials. Figures 3.1 – 3.6 
show representative chromatograms for blank and internal standard plus zero, 
0.20, 0.50, 11.00, 16.00 µg/ml of ketoconazole in plasma. 
 
 
 
Figure 3.1. Chromatogram of Blank plasma  
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Figure 3.2. Chromatogram of blank plasma spiked with itraconazole as 
internal standard 
 
 
 
 
 
 
Figure 3.3. Chromatogram of plasma spiked with 0.2 µg/ml of 
ketoconazole (Rt = 2.03 min) and itraconazole (Rt = 5.23 min) 
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Figure 3.4. Chromatogram of plasma spiked with 0.5 µg/ml of 
ketoconazole (Rt = 2.03 min) and itraconazole (Rt = 5.23 min) 
 
 
 
 
 
Figure 3.5. Chromatogram of plasma spiked with 11 µg/ml of 
ketoconazole (Rt = 2.03 min) and itraconazole (Rt = 5.23 min) 
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Figure 3.6. Chromatogram of plasma spiked with 16 µg/ml of 
ketoconazole (Rt = 2.03 min) and itraconazole (Rt = 5.23 min) 
 
 
 
Figure 3.7. Calibration curve of ketoconazole in plasma (r =0.992705) 
 
Quantitation was achieved by measurement of the peak area ratio of 
the drug to the internal standard. The linearity for ketoconazole in plasma in a 
range of concentration of 0.20-20 µg/ml and through a range of concentration 
50-6000 ng/ml was validated. Standard curves of ketoconazole were analyzed 
at concentrations 0.20, 0.50, 1.00, 2.00, 5.00, 10.00, 15.00, and 20.00 µg/ml. 
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Good linearity was achieved (R2 = 0.992705). Calibration curve of 
ketoconazole in plasma is illustrated in figure 3.7. 
 
3.2.  Pharmacokinetics of ketoconazole tablets; 400 mg regimen 
 
Tables 3.1 illustrates individual plasma concentration versus time 
profiles of ketoconazole after its oral administration to 6 patients. The plasma 
concentrations of ketoconazole after the first dose (single, 400 mg) are 
represented by samples number 1 to 11. Samples number 12 to 27 represent 
plasma concentration following the administration of repeated doses of 
ketoconazole (up to six months, 200 mg twice a day). Samples 28 to 38 
correspond to plasma concentrations following the administration of the last 
dose (single, 400 mg) of ketoconazole tablets. The table shows the individual 
variation between the subjects. Most of the patients finished the first three 
months of therapy and stopped, except for two. One patient did not complete 
the full course of the trial and dropped out following the first week and the 
other patient completed the whole six months of the trial. Therefore, data 
following the administration of the last dose is represented by only one 
patient. 
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Table 3.1: Ketoconazole Plasma concentration (µg/ml) versus time (h) 
following oral administration of 400 mg regimen for 6 patients. 
 
Sample 
No. 
Time 
(h) Day Weeks BH NO EM FO RH SY Mean SD C V%
1 0 1 0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0 
2 1   1.19 7.95 1.38 6.31 2.52 9.35 4.78 3.54 74.11
3 2   5.69  2.82 8.50 10.32 9.65 7.40 3.11 42.06
4 3   15.07 8.09 2.73  6.26 6.16 7.66 4.57 59.67
5 4   12.21 7.38 1.17 4.26 5.29 4.85 5.86 3.70 63.18
6 6   8.70 4.26 0.37 4.31 3.42 2.96 4.00 2.71 67.81
7 8   8.21 2.80 0.21 2.86 2.84 2.28 3.20 2.66 83.02
8 12   3.86 1.25  1.29 1.17 1.70 1.85 1.14 61.49
9 16   1.40 0.66  1.10 0.38 1.00 0.91 0.40 43.63
10 20   1.25 0.63 0.61 0.93   0.86 0.30 35.24
11 24    0.70 0.50 0.47   0.56 0.13 22.46
12 192 7 1  6.26 0.71 2.75 1.40 0.82 2.39 2.31 96.80
13 194   4.27 14.03 3.63 8.96 1.56 4.33 6.13 4.57 74.49
14 360 14 2  1.54 0.95 0.25  0.59 0.83 0.55 66.25
15 362    14.91 5.91 4.74  5.32 7.72 4.82 62.40
16 528 21 3  4.27  1.22   2.75 2.16 78.57
17 530    12.79  5.41   9.10 5.22 57.35
18 1368 56 8 5.12 3.78  1.29  0.49 2.67 2.15 80.59
19 1370   6.75 5.32 4.75 10.18  7.22 6.84 2.12 30.98
20 2040 84 12 2.46 0.28 1.62 6.05   2.60 2.47 94.81
21 2042   7.22 13.24 5.53   14.78 10.19 4.51 44.21
22 2904 119 17  0.72  6.06  7.47 4.75 3.56 74.96
23 2906    13.81     13.81  0.00 
24 3552 147 21  5.82    2.76 4.29 2.16 50.44
25 3554    12.81    9.99 11.40 1.99 17.49
26             
27             
28 4224 0 25  3.34        
29 4225 1   3.67        
30 4226 2   5.27        
31 4227 3   5.92        
32 4228 4   9.49        
33 4230 6   11.56        
34 4232 8   9.92        
35 4236 12   6.62        
36 4240 16   5.04        
37 4244 20   4.34        
38 4248 24   2.46        
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Plasma concentrations versus time profiles following oral administration 
of 400 mg ketoconazole to 6 patients were illustrated in figures 3.8, 3.9, 3.10, 
3.11, 3.12, and 3.13. 
 
A total of fifteen samples were collected from patient BH in 3 month as 
shown in figure 3.8. The highest concentration achieved following the first 
dose was 15.07 µg/ml in 3 hrs, the levels declined to 1.25 µg/ml in 20 hrs and 
fluctuated between 6.75, 2.46 and 7.22 µg/ml following the administration of 
the repeated dose for 2 month. It is worth mentioning that this patient showed 
the highest levels among all volunteers. 
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Figure 3.8: Plasma concentration-time profile following the administration of 
400 mg ketoconazole regimen to patient BH 
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Thirty five samples were collected from patient NO during 6 months. These 
characterize the full profile as described in the study protocol. The plasma 
concentration – time profile was plotted in figure 3.9. The concentration 
increased until it reached a maximum of 8.09 µg/ml in 3 hrs in the first day 
then declined to 0.7 µg/ml in 24 hrs. At steady state plasma levels fluctuated 
between trough and peak concentrations for six months. The profile shows a 
maximum of 11.56 µg/ml in 6 hrs following the administration of the last dose 
and a decrease to 2.46 µg/ml in 24 hrs. 
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Figure 3.9: Plasma concentration-time profile following the administration of 
400 mg ketoconazole regimen to patient NO 
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Few samples were analyzed for patient EM; about sixteen samples which are 
represented in figure 3.10. The levels of this patient represent the lowest 
concentrations compared to those of the other 6 patients. His concentration 
increased and reached a maximum of only 2.82 µg/ml in 2 hrs and then 
gradually declined to 0.5 µg/ml in 24 hrs. The levels increased to a maximum 
concentration and decreased to a minimum concentration during the next 12 
weeks. 
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Figure 3.10: Plasma concentration-time profile following the administration of 
400 mg ketoconazole regimen to patient EM 
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Figure 3.11 depicts the plasma concentration against time profile 
for patient FO. This patient complied with the sampling schedule till the 17th 
week where the last two peak samples were observed to be missing. The 
profile shows increase to a maximum concentration of 8.5 µg/ml in 2 hrs 
following the administration of the first dose and a decline to 0.47 µg/ml in 24 
hrs. Fluctuation between maximum and minimum concentrations at steady 
state was presented for multiple dose administration till week 17. 
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Figure 3.11: Plasma concentration-time profile following the administration of 
400 mg ketoconazole regimen to patient FO 
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Eleven samples only were collected from patient RH. This patient 
dropped from the study after the first week. Plasma levels are illustrated in 
figure 3.12 where the concentration increased after 2 hrs to 10.32 µg/ml and 
decreased to 0.38 µg/ml in 16 hours. Only one peak and one trough samples 
were collected. 
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Figure 3.12: Plasma concentration-time profile following the administration of 
400 mg ketoconazole regimen to patient RH 
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Patient SY provided twenty one samples, the levels of these samples 
increased and reached a maximum of 9.65 µg/ml after 2 hrs then decreased 
gradually until 1.0 µg/ml in the first day. At the first week plasma 
concentrations measured immediately before the dose and 2 hours after 
administration of the dose were found to be 0.82 and 4.33 µg/ml, respectively. 
The levels fluctuated between trough and peak concentrations for five 
months. The last trough and peak levels reported were 0.27 and 5.37 µg/ml, 
respectively. The highest concentration achieved by this patient was 14.78 
µg/ml following 3 moths of therapy (figure 3.13). 
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Figure 3.13: Plasma concentration-time profile following the administration of 
400 mg ketoconazole regimen to patient SY 
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Figure 3.14 represents the plasma concentration – time profiles for the 
6 patients after oral administration of ketoconazole 400 mg regimen. As can 
be seen in the figure, most patients finished three months of the study. On the 
other hand, one patient (RH) finished only the first week of sampling while 
patient SY stopped after five months. Only one patient (NO) was able to 
complete the full course of the trail. From sample number 28 the graph shows 
the plasma concentrations for this patient. Interindividual variability was 
observed between the patients.  
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Figure 3.14: Plasma concentration-time profile following the administration of 
400 mg ketoconazole regimen to 6 mycetoma patient  
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Mean (± SE) plasma concentration versus time profiles of ketoconazole 
tablets following the administration of 400 mg regimen to 6 patients is 
depicted in figure 3.15. No error bars were included in the last part of the 
profile since the data is collected from only on patient. 
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Figure 3.15: Mean (± SE) plasma concentration-time profile following the 
administration of ketoconazole 400 mg regimen to 6 mycetoma 
patients 
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Figures 3.16 and 3.17 represent individual plasma concentration against time 
profiles of the six patients and the mean (± SE) plasma concentration of 
ketoconazole tablets following the administration of the first dose of 400 mg 
regimen, respectively. The profiles for the majority of the patients were similar 
except for two patients. One patient (EM) showed the lowest plasma levels 
while patient BH showed the highest levels following the administration of the 
first dose. 
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Figure 3.16: Plasma concentration-time profile following administration of the 
first dose of 400 mg ketoconazole regimen to 6 mycetoma 
patients 
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After plotting Mean (± SE) plasma concentration versus time following the 
administration of first dose of 400 mg ketoconazole regimen in figure 3.17, the 
concentration started to increase from 0 until it reached a maximum 
concentration of 7.66 µg/ml at 3 hrs and then decline. 
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Figure 3.17: Mean (± SE) plasma concentration-time profile following the 
administration of the first dose 400 mg ketoconazole regimen to 
mycetoma patients (n = 6) 
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Figures 3.18 and 3.19 represent the plasma concentration versus time 
profiles of first and last dose for 400 mg regimen for patient NO. 
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Figure 3.18: Plasma concentration-time profile following administration of the 
first dose of 400 mg ketoconazole regimen to patient NO 
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Figure 3.19: Plasma concentration-time profile following administration of the 
last dose of 400 mg ketoconazole regimen to patient NO 
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Comparison of first and last doses of 400 mg regimen for patient NO, 
the only one who completed the trial, is shown in figure 3.20. In the first dose 
profile the concentration started to increase from 0 to a maximum 
concentration of 8.09 µg/ml at 3 hrs and then decreased. While in the last 
dose profile the concentration started from 3.34 µg/ml achieved highest 
concentration of 11.56 µg/ml at 6 hrs then declined gradually as exposed in 
figure 3.20 to 2.46 µg/ml. it has been observed that there is a shift of the 
profile upward and to the right. 
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Figure 3.19: Plasma concentration-time profile following administration of the 
first and last dose of 400 mg ketoconazole regimen to patient 
NO 
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Table 3.2. ketoconazole pharmacokinetic parameters after oral 
administrations of the first dose of 400 mg regimen to 6 
eumycetoma patients. 
 
Parameter 
Patient Tmax 
(h) 
Cpmax 
(µg/ml) 
AUC∞ 
(µg.h/
ml) 
AUMC 
(µg.h2/
ml) 
MRT 
(h) 
Ke 
(h-1) 
t1/2 
(h) 
 
CL/F 
(L/h) 
Vd/F 
(L) 
AUC24 
(µg.h/ml) 
 
BH 3.00 15.07 113.83 968.37 8.51 0.16 4.43 3.51 22.47  
NO 3.00 8.09 67.13 499.27 7.44 0.20 3.48 5.96 29.94 63.61 
EM 2.00 2.82 17.82 187.31 10.51 0.48 1.45 22.45 46.94 16.78 
FO 2.00 8.50 63.77 578.55 9.07 0.10 7.04 6.27 63.70 59.00 
RH 2.00 10.32 49.91 295.81 5.93 0.18 3.79 8.01 43.82  
SY 2.00 9.65 61.56 459.41 7.46 0.13 5.27 6.49 49.35  
Mean 2.33 9.08 62.34 498.12 8.15 0.21 4.24 8.78 42.70 46.46 
SD 0.52 3.96 31.03 270.79 1.58 0.14 1.87 6.85 14.67 25.81 
C V% 22.32 43.61 49.78 54.36 19.39 66.67 44.10 78.02 34.36 55.55 
 
 
 
Table 3.3: Ketoconazole pharmacokinetic parameters after oral 
administrations of the last dose of 400 mg regimen to patient NO. 
 
Parameter 
Patient 
Tmax 
(h) 
Cpmax 
(µg/ml) 
AUC∞ 
(µg.h/
ml) 
AUMC 
(µg.h2/ 
ml) 
MRT 
(h) 
Ke 
(h-1) 
t1/2 
(h) 
 
CL/F 
(L/h) 
Vd/F 
(L) 
AUC24 
(µg.h/ml) 
NO 6.00 11.56 183.07 2681.67 14.65 0.08 8.60 1.09 13.55 152.57 
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Tables 3.2 and 3.3 represent the pharmacokinetic parameters of 400 
mg following the first and last doses, respectively achieved after oral 
administration of ketoconazole tablets. 
The mean (± SD) values of maximum drug concentration (Cpmax) after 
oral administration of the first and last doses of 400 mg regimen are in the 
order of 9.08 ± 3.96 µg/ml (range, 2.82 – 15.07 µg/ml) and 11.56 µg/ml 
(values generated from data of only one patient). coefficient of variation 
(CV%) following the administration of the first dose was 43.59%. On the other 
hand, the mean values of times to reach Cpmax (Tmax) were found to be 2.33 ± 
0.52 hr (range, 2 – 3 hrs, CV% = 22.13%) following first dose and 6 h after 
last dose. 
The mean (± SD) values of AUC∞ and AUMC∞ for ketoconazole 
obtained after oral administration of first dose of 400 mg regimen were 62.34 
± 31.03 µg.h/ml (range, 17.82 – 113.83 µg.h/ml) and 498.12 ± 270.79 µg.h2/ml 
(range, 187.31 – 968.37 µg.h2/ml), respectively. Values obtained after oral 
administration of last dose were 183.07 µg.h/ml and 2681.67 µg.h2/ml. CV% 
following the first dose were estimated as 49.77% and 54.36% for AUC∞ and 
AUMC∞, respectively. Comparing the AUCs of three patients, the percentage 
AUC24 in relation to the AUC∞ was 94%. This indicates that the estimated 
areas were less than 10% of the total area. This is a proof of the accuracy of 
the sampling schedule. 
The mean (± SD) values of MRT were determined as 8.15 ± 1.58 hr 
(range, 5.93 – 10.51 hrs) and 14.65 hr following ingestion of first and last 
doses, respectively. 
CL/F values (mean ± SD) for 400 mg ketoconazole regimen were found 
to be 8.78 ± 6.85 L/h (range, 3.51 - 22.45 L/h, CV% = 77.98%) and 1.09 L/h 
for first dose and last doses, respectively.  
Vd/F values (mean ± SD) were found to be in the sequence of 42.70 ± 
14.67 L (range, 22.47 – 63.70 L and CV% 34.35%) and 13.55 L for first dose 
and last doses of 400 mg ketoconazole regimen.  
The mean (± SD) values of the elimination half - life (T1/2) for 
ketoconazole are calculated as 4.24 ± 1.87 hr (range, 1.45 – 7.04 hrs) and 
8.60 hr following the first and last doses of the 400 mg regimen, respectively. 
Coefficient of variation for the values of half – life was 44.07%. 
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3.3. Pharmacokinetics of ketoconazole tablets; 800 mg regimen 
Table 3.4 represent the individual plasma concentrations of all doses, 
first dose and last dose, respectively after oral administration ketoconazole 
tablets 800 mg regimen to 6 patients. Individual variations between the 
patients are observed.  
Tables 3.4 represents individual plasma concentration-time profiles of 
ketoconazole after oral administration of the 800 mg regimen to 6 
eumycetoma patients. The sampling schedule was the same as that of the 
400 mg regimen. The plasma concentrations after the first dose (single, 800 
mg) are represented by samples number 1 to 11. Samples number 12 to 27 
represent plasma concentration following multiple dose administration of 
ketoconazole (up to six months, 400 mg twice a day). Samples 28 to 38 
correspond to plasma concentrations following the administration of the last 
dose (single, 800 mg) of ketoconazole tablets. Unlike the first regimen, patient 
compliance was quite reasonable. Most of the patients finished six months of 
therapy except for two patients (SE and OE) who stopped after two weeks of 
sampling. Interindividual variations between the subjects were noted to the 
same extent as those in the 400 mg regimen (variable CV% values). 
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Table 3.4:  Ketoconazole Plasma concentration (µg/ml) versus time (h) 
following oral administration of 800 mg regimen for 6 patients. 
Sample 
No. 
Time 
(h) Day Weeks LAA SH AAO SE AAM OE Mean SD CV% 
             
1 0 1 0 0 0 0 0 0 0 0.00 0.00 0 
2 1   6.01 11.2 10 17.1 4.3 9.1 9.61 4.47 46.5 
3 2   10.2 14.7 16 30.4 9.4 21 16.92 7.80 46.1 
4 3   11.9 11.1 14 27 3.7 18 14.41 7.85 54.5 
5 4   5.75 8.15 11 21.2 2.9  9.83 7.04 71.6 
6 6   5.16 3.32 5  2.9 8.8 5.03 2.32 46.1 
7 8    3.72    7 5.37 2.33 43.4 
8 12   2.41 2.24 2.5 10.4 1.2 4.1 3.79 3.37 89.0 
9 16   1.07 1.24 0.7 2.59 0.3 1.8 1.29 0.80 62.3 
10 20    1.11  1.54  1 1.21 0.30 24.6 
11 24    0.88  0.56  0.4 0.62 0.24 38.9 
12 192 7 1  1.01  6.81  9.1 5.62 4.15 73.8 
13 194    9.72 15 11.1 7 19 12.28 4.54 37.0 
14 360 14 2   8.7 5.74 0.6 3.2 4.57 3.48 76.1 
15 362    9.01 15 13.7 6.4 21 12.97 5.57 42.9 
16 528 21 3 8.67  4.9  0.8  4.78 3.96 82.8 
17 530   12.8 12.8 13  1.9  10.21 5.56 54.5 
18 1368 56 8 4.8 8.42 0.3  1.1  3.66 3.73 102.0 
19 1370   14.7 13.8 16  3.9  12.09 5.57 46.1 
20 2040 84 12  7.76 0.4  0.9  3.01 4.12 136.7 
21 2042   9.55 8.86 8.7  3.6  7.66 2.75 35.9 
22 2904 119 17   7.6    7.55  0.0 
23 2906   7.58  11  4.2  7.52 3.31 43.9 
24 3552 147 21 5.18  6  3.4  4.86 1.36 28.0 
25 3554   14.5  13  3.5  10.40 6.00 57.7 
26      5.3  1.6  3.44 2.65 77.2 
27      15  12  13.62 1.84 13.5 
28 4224 0 25 4.62 0.72   0.5  1.95 2.31 118.3 
29 4225 1  4.9 7.8 8.8  4.4  6.48 2.18 33.7 
30 4226 2  15.6 18.4 18  11  15.75 3.23 20.5 
31 4227 3  12.3 14.2   9  11.82 2.66 22.5 
32 4228 4  10.6 9.52   5.1  8.39 2.92 34.8 
33 4230 6  5.34 7.8   4.8  5.99 1.59 26.6 
34 4232 8  13.7 7.43   3.6  8.26 5.11 61.9 
35 4236 12  12.4 18.3 4  3.1  9.45 7.22 76.4 
36 4240 16  19.3 16.9   2.8  13.03 8.92 68.4 
37 4244 20  13.3 13.3 1.3  1.5  7.35 6.87 93.5 
38 4248 24  8.31 9.27 1.2  0.6  4.84 4.58 94.6 
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The plasma concentration versus time graphs for ketoconazole 
following oral administration of 800 mg regimen for all patients are illustrated 
in figures 3.21 - 3.26. 
Twenty seven samples were collected from patient LAA, the plasma 
concentration versus time is depicted in figure 3.21. Plasma levels started at 0 
and accomplished a maximum of 11.88 µg/ml at 3 hrs and then fell to 1.07 
µg/ml in 16 hr during the first day. Samples numbers 10 – 15 were not 
collected. The patient resumed providing blood samples at week 3. From this 
period till the last day of sampling, the levels fluctuated between blood 
samples taken pre dose (trough concentration) and post dose (peak 
concentration. Interestingly, two maxima were observed in the last day where 
the concentration was raised from 4.62 µg/ml reached a maximum of 15.56 
µg/ml in 2 hrs and fall to 5.34 µg/ml. The other maximum was observed (19.34 
µg/ml) at 16 hours. Following the second maximum, plasma levels were 
dropped to 8.31 µg/ml in 24 hours period. 
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Figure 3.21: Plasma concentration-time profile following administration of 800 
mg ketoconazole regimen to patient LAA. 
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Patient SH showed plasma concentrations that are comparable to the 
majority of the patients (figure 3.22). His levels started from 0 µg/ml 
reached a ceiling of 14.68 µg/ml at 2 hrs and then fell to 0.88 µg/ml after 
24 hrs. The highest concentration seen after 8 weeks was 13.78 µg/ml. In 
the last 24 hrs the profile of this patient was observed to similar to that of 
previous patient (LAA). Concentration increased from 0.72 µg/ml and 
attained a first peak level of 18.38 µg/ml at 2 hrs and another level of 
18.27 µg/ml in 12 hours. This may due to the fact that the two patients took 
the drug twice instead of once in the last day. The total number of samples 
collected from this patient was 30 samples. 
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Figure 3.22: Plasma concentration-time profile following administration of 800 
mg ketoconazole regimen to patient SH. 
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Figure 3.23 represents the plasma concentration versus time for 28 
plasma samples taken from patient AAO. For the first 24 hrs ketoconazole 
concentration began at 0 µg/ml reached a maximum of 16.21 µg/ml in 2 hrs 
and then declined to 0.71 µg/ml in 16 hours. The levels fluctuated between 
minimum and maximum steady state concentration for the next period; till six 
months of therapy. The concentration increased after dosing as observed in 
the last day from 8.84 µg/ml to achieve a peak of 17.81 µg/ml in 2 hrs then 
decreased to 1.19 in 24 hrs. It has been observed that samples 10 – 12 and 
31 – 34 are missing. 
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 Figure 3.23: Plasma concentration-time profile following administration of 800 
mg ketoconazole regimen to patient AAO. 
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Only 13 plasma samples were obtained from patient SE (figure 3.24) 
since he dropped out of the study on the second week. This Patient showed 
the highest ketoconazole concentrations in relation to the other six patients. 
Following the administration of the first dose, the patient showed maximum 
concentration of 30.42 µg/ml detected after 2 hrs. The decreased steadily to a 
level of 0.56 in 24 hours. 
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Figure 3.24: Plasma concentration-time profile following administration of 800 
mg ketoconazole regimen to patient SE. 
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Plasma concentration – time profiles for patient AAM is demonstrated 
in figure 3.25. Thirty three blood samples were obtained, which represent the 
lowest levels measured among all the patients. The concentration started 
from 0 µg/ml and achieved 9.38 µg/ml after 2 hrs then decreased to 0.34 
µg/ml after 16 hrs. Fluctuation at steady state continued till the 6th month. In 
the last 24 hrs of sampling schedule, the concentration increased from 0.52 to 
a maximum of 11.26 µg/ml in 2 hrs then drop dawn to 0.6 µg/ml in 24 hours. 
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 Figure 3.25: Plasma concentration-time profile following administration of 800 
mg ketoconazole regimen to patient AAM. 
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Patient OE attended 2 weeks of sampling only with 14 samples 
analyzed to obtain the profile drawn in figure 3.26. As can be seen in the 
profile the maximum concentration of ketoconazole attained by this patient is 
20.66 µg/ml observed after 2 hrs following the administration of the first dose. 
The levels then decrease to 0.41 µg/ml in 24 hours. The profile shows levels 
fluctuating between trough and peak concentrations for week 1 and 2. 
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Figure 3.26: Plasma concentration-time profile following administration of 800 
mg ketoconazole regimen to patient OE. 
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A plot of the plasma levels of ketoconazole following its administration 
to the six patients is shown in figure 3.27. The first part of the profile was 
consistent with respect to the time to reach maximum concentration. 
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Figure 3.27: Plasma concentration-time profile following administration of 800 
mg ketoconazole regimen to 6 mycetoma patients. 
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Figure 3.28 illustrates the Mean (± SE) plasma concentration versus 
time following the administration of 800 mg ketoconazole regimen to 6 
mycetoma patients. The mean (± SD) maximum concentration attained is 
16.92 ± 7.8 µg/ml achieved after 2 hrs. The concentration decreased to 0.62 ± 
0.24 after 24 hours. Following the first day of treatment plasma concentration 
repeatedly decreased and increased till the last day of therapy. Two maxima 
were observed following the administration of ketoconazole on the last day. 
The first one occurred after 2 hours 15.75 µg/ml and the second one at 16 
hours 13.03 µg/ml following drug administration. The average is greatly 
influenced by two patients (LAA and SH) who probably ingested the drug 12 
hours a part instead of a single 800 mg once. 
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Figure 3.28: Mean (± SE) plasma concentration-time profile following the 
administration of 800 mg ketoconazole regimen to 6 mycetoma 
patients 
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When evaluating the plasma concentration versus time following the 
administration of the first dose of the 800 mg ketoconazole regimen, the 6 
mycetoma patients showed consistent profiles (figure 3.29). Interestingly, the 
maximum concentration was attained in 2 hours for all the patients except for 
one (LAA) who achieved maximum level in 3 hours. 
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figure 3.29: Plasma concentration - time profiles following the administration 
of the first dose  800 mg ketoconazole regimen in 6 mycetoma 
patients 
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In figure 3.30 the mean (± SE) plasma concentration-time values were 
plotted following the administration of the first 800 mg dose. Average 
maximum concentration of 16.92 (± 7.8) µg/ml was achieved after an average 
Tmax of 2.17 (± o.41) hrs. The levels then dropped to an average of 0.62 (± 
0.24) µg/ml in 24 hours. 
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Figure 3.30: Mean (± SE) Plasma concentration - time profiles following the 
administration of the first dose 800 mg ketoconazole regimen to 
6 mycetoma patients 
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Individual and average (± SE) plasma concentration-time profiles 
following the administration of the last dose of ketoconazole to Mycetoma 
patients (n = 4) are depicted in figures 3.31 and 3.32, respectively. 
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Figure 3.31: Plasma concentration-time profiles following the administration of 
the last dose 800 mg ketoconazole regimen to 4 mycetoma 
patients 
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As can be seen in figure 3.32, the concentration increased from 1.95 ± 
2.31 µg/ml reached a maximum of 15.75 ± 3.23 µg/ml after 2 hrs and dropped 
to 11.82 ± 2.66 µg/ml and increased again to 13.03 ± 8.92 µg/ml after 16 hrs 
and declined to 4.84 ± 4.58 µg/ml in the last 24 hrs of sampling. The profile 
seems like a double peak pharmacokinetic phenomena. It is known that 
ketoconazole kinetics shows these phenomena. The double peaks in serum 
concentration, seen at higher doses of ketoconazole, raise the question of 
enterohepatic circulation or delayed absorption (Brass et al, 1982).  
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Figure 3.32.  Mean (± SE) Plasma concentration - time profiles following the 
administration of the last dose 800 mg ketoconazole regimen for 4 
mycetoma patients 
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When comparing the concentrations after the first and last doses of the 
800 mg ketoconazole regimen (figure 3.33) during the first 6 hours; the first 
dose achieved higher peak concentration (16.92 ± 7.8 µg/ml) than the last 
dose (15.75 ± 3.23 µg/ml). The corresponding times to peaks are 2 hours for 
the two doses.  
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Figure 3.33: Mean (± SE) plasma concentration-time profile following the 
administration of the first and last dose of 800 mg ketoconazole 
regimen to mycetoma patients (n = 6) 
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Figures 3.34 demonstrate the mean (± SE) plasma concentration 
versus time profiles of ketoconazole for the tow regimens. Concentrations 
attained when the patients were given the 800 mg ketoconazole regimen were 
higher compared with 400 mg ketoconazole regimen. 
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Figure 3.34: Mean (± SE) plasma concentration-time profile following the 
administration of the 400 mg and 800 mg ketoconazole regimen to 
12 mycetoma patients 
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Tables 3.5 and 3.6 represent the pharmacokinetic parameters of 800 
mg ketoconazole tablets following the administration of the first and last doses 
to six Mycetoma patients, respectively 
The mean (± SD) values of maximum drug concentration (Cpmax) of 
800 mg ketoconazole regimen after administration of first dose was found to 
be 17.21 ± 7.53 µg/ml (range, 9.38 – 20.65 µg/ml) and that for last dose was 
18.44 ± 7.35 µg/ml (range, 11.26 – 28.54 µg/ml). The coefficients of variations 
(CV %) are 43.77% and 39.84%, respectively. 
The mean (± SD) values of maximum time to reach Cpmax (Tmax) for 
800 mg ketoconazole regimen after administration of first dose and last dose 
were found to be 2.17 ± 0.41 h (range, 2 - 3 h, CV% 18.84%) and 2.00 ± 0.82 
h (range, 1 - 3 h, CV% 42.82%), respectively.  
The mean (± SD) of AUC∞ and AUMC∞ following the administration of a 
single dose of 800 mg ketoconazole are in the sequence of 121.56 ± 71.52 
µg.h/ml (range, 41.27 – 252.19 µg.h/ml and CV%, 58.84%) and 959.40 ± 
597.39 µg.h2/ml (range, 235.85 – 1775.01 µg.h2/ml and CV%, 62.27%) for 
first dose and 264.56 ± 136.96 µg.h/ml (range, 87.97 – 378.30 µg.h/ml, CV%, 
51.77%) and 3644.23 ± 2930.57 µg.h/ml (range, 998.77 – 6460.04 µg.h/ml, 
CV%, 80.42%) for last dose. The percentages of AUC24, AUC20 and even 
AUC16 of three patients in relation to their AUC∞ were 97.7%, 95.4% and 
91.6% respectively. This indicates that the estimated areas were less than 
10% of the total area. This proofs the accuracy of the proposed sampling 
schedule. 
MRT values (mean ± SD) are found to be 7.86 ± 3.28 h (range, 5.42 - 
14.28 h) and 12.49 ± 5.29 h (range, 5.49 - 17.08 h) following the 
administration of first and last doses. The corresponding coefficients of 
variations are 41.73% and 42.34%. 
The estimated mean (± SD) values of CL/F were 8.79 ± 5.57 L/h 
(range, 3.17 – 19.38 L/h, CV% = 63.44%) and 3.18 ± 2.48 L/h (range, 1.59 - 
6.82 L/h, CV% = 78.03%) after first dose and last dose, respectively.  
The mean (± SD) values of Vd/F were in the order of 49.28 ± 27.11 L 
(range, 17.23 – 96.61 L, CV%, 55.01%) and 36.66 ± 40.14 L (range. 10.91 – 
96.27 L, CV%, 109.51%) after 800 mg first dose and 800 mg last dose. 
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The calculated mean (± SD) values of the elimination half - life (T1/2) of 
ketoconazole were 4.00 ± 0.66 h (range, 3.23 – 4.98 h, CV%, 16.45%) and 
6.83 ± 2.15 (range, 4.63 – 9.78 h, CV%, 31.49%) following the first dose and 
last doses, respectively.  
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Table 3.7: Mean (± SD) pharmacokinetic parameters of Ketoconazole for the 
tow regimen 
Parameter 400 mg 1
st 
dose P - value*
400 mg 
last 
dose** 
800 mg 1st 
dose 
800 mg last 
dose P - value *** 
Tmax (h) 2.33 ± 0.52 0.18 6.00 2.17 ± 0.41 2.00 ± 0.82 0.36 
Cmax 
(µg/ml) 9.08 ± 3.96 0.04 11.56 
17.21 ± 
7.53 18.44 ± 7.35 0.40 
AUC∞ 
(µg.h/ml) 
62.34 ± 
31.03 0.05 183.07 
121.56 ± 
71.52 
264.56 ± 
136.96 0.06 
AUMC 
(µg.h2/ml) 
498.12 ± 
270.79 0.02 2681.67 
95940 ± 
597.39 
3644.23 ± 
2930.57 0.08 
MRT (h) 8.15 ± 1.58 0.43 14.65 7.86 ± 3.28 12.49 ± 5.29 0.09 
Ke (h-1) 0.21 ± 0.14 0.28 0.08 0.18 ± 0.03 0.11 ± 0.03 0.01 
T1/2 (h) 4.24 ± 1.87 0.38 8.60 4.00 ± 0.66 6.83 ± 2.15 0.04 
CL/F (L/h) 8.78 ± 6.85 0.5 1.09 8.79 ± 5.57 3.18 ± 2.48 0.03 
Vd/F (L) 42.70 ± 14.67 0.34 13.55 
49.28 ± 
27.11 36.66 ± 40.14 0.30 
AUC 24 
(µg.h/ml) 
46.46 ± 
25.81 0.21 152.57 
157.92 ± 
82.94 
244.56 ± 
105.39 0.20 
 
 
 * Estimated p value for 400 mg 1st dose and 800 mg 1st dose 
 ** Values obtained from only one patient. 
 *** Estimated p value for 800 mg 1st dose and 800 mg last dose 
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3.4. Comparisons of pharmacokinetic parameters of ketoconazole 
following administration of the two regimens 
Comparisons of pharmacokinetic parameters of ketoconazole following 
its administration as 400 mg and 800 mg regimens are shown in table 3.7. 
 
3.4.1. Comparisons following the administration of the first dose of the 
two regimens 
The peak concentrations achieved after 400 mg (9.08 ± 3.96 µg/ml) is 
almost double that following the administration of 800 mg ketoconazole (17.21 
± 7.53 µg/ml). On the other hand, the mean times to reach Cpmax (Tmax) were 
comparable between the two dosing regimens (2.33 ± 0.52 and 2.17 ± 0.41, 
respectively). 
The mean values of AUC∞ are found to be 62.34 ± 32.03 µg.h/ml for 
400 mg regimen and 121.56 ± 71.52 µg.h/ml for 800 mg regimen. While the 
estimated values of AUMC∞ were 498.12 ± 270.79 µg.h2/ml and 959.4 ± 
597.39 µg.h2/ml. 
The obtained values for MRT, Ke and t1/2 were 8.15 ± 1.58 and 7.86 ± 
3.28 h; 0.21 ± 0.14 and 0.18 ± 0.03 h; 4.24 ± 1.87 and 4 ± 0.66 h for 400 and 
800 mg regimens, respectively. 
The physiological parameters Cl/F and Vd/F were estimated as 8.78 ± 
6.85 and 8.79 ± 5.57 L/h; 42.7 ± 14.67 and 49.28 ± 27.11 L for the two 
regimens. 
 
3.4.2. Comparisons following the administration of the last dose of the 
two regimens 
 
 The data obtained following the last dose was compared between the 
mean of four patients in the 800 mg regimen and only one patient in the 400 
mg regimen. 
The peak concentrations reached following the administration of 400 
mg ketoconazole were 11.56 µg/ml compared to that of 800 mg ketoconazole 
(18.44 ± 7.35 µg/ml). The values of Tmax between the two dosing regimens 
were 6.0 and 2.00 ± 0.82, respectively. 
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The mean values of AUC∞ are found to be 183.07 µg.h/ml for 400 mg 
regimen and 264.56 ± 136.96 µg.h/ml for 800 mg regimen. While the 
estimated values of AUMC∞ were 2681.67 µg.h2/ml and 3644.23 ± 2930.57 
µg.h2/ml. 
The calculated parameters MRT, Ke and t1/2 were found to be 14.65 
and 12.49 ± 5.29 h; 0.08 and 0.11 ± 0.03 h; 8.6 and 6.83 ± 2.15 h for 400 and 
800 mg regimens, respectively. 
The physiological parameters Cl/F and Vd/F were estimated as 1.09 
and 3.18 ± 2.48 L/h ; 13.55 and 36.66 ± 40.14 L for the two regimens, 
respectively. 
 
3.4.3. Comparisons of steady state levels 
Plasma concentration fluctuated between minimum steady state 
concentrations (Cpssmin) of 2.68 ± 1.40 (CV%, 52.13%) and 4.18 ± 0.98 (CV%, 
23.52%) and maximum steady state concentrations (Cpssmax) of 8.00 ± 1.65 
(CV%, 20.67) and 11.97 ± 3.24 (CV%, 27.07%) following the administration of 
the 400 mg and 800 mg ketoconazole regimens, respectively. 
The corresponding fluctuation at steady state (F, calculated as 
Cpssmax/Cpssmin) was found to be 3.98 ± 3.01 for the 400 mg regimen and 2.96 
± 0.93 for the 800 mg regimen  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  113
Table 3.8 Steady state pharmacokinetic of ketoconazole following its 
administration as 4oo and 800 mg regimens  
Dose 
400 MG 800 MG  
trough Cp peak Cp fluctuation 
trough 
Cp 
peak 
Cp fluctuation 
2.39 6.13 2.56 5.62 12.28 2.19 
0.83 7.72 9.30 4.57 12.97 2.84 
2.75 9.10 3.31 4.78 14.71 3.08 
2.67 6.84 2.56 3.66 16.59 4.53 
4.75 10.19 2.15 2.48 7.66 3.09 
- - - 4.05 7.52 1.86 
- - - 4.86 10.40 2.14 
C
on
ce
nt
ra
tio
n
 
- - - 3.44 13.62 3.96 
Mean 2.68 8.00 3.98 4.18 11.97 2.96 
SD 1.40 1.65 3.01 0.98 3.24 0.93 
CV% 52.13 20.67 75.60 23.52 27.08 31.30 
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4. Discussion 
 
There are many studies on pharmacokinetics of ketoconazole 
preparations in healthy volunteers and patients. There are also some animal 
studies. Some objectives of these studies were to assess the clinical use and 
adverse effects of ketoconazole. In the present study the pharmacokinetics 
and clinical efficacy of two dosing regimens of ketoconazole in eumycetoma 
patients were investigated. 
 
4.1. Analytical procedure 
 
Different analytical procedures were used to determine the 
concentration of ketoconazole in biological fluids. In this study we evaluated 
the pharmacokinetic parameters and bioavailability by means of HPLC. The 
HPLC procedure was specific, sensitive and selective for the determination of 
ketoconazole and itraconazole the internal standard in plasma. Reasonable 
retention times were achieved for ketoconazole (2.03 minutes) and 
itraconazole (5.23 minutes) with a total run time of 6 minutes. 
Chromatograms showed no interfering peaks and good regression (R2 = 
0.992705) of the calibration curves was achieved. The limit of quantification 
was 50 ng/ml. 
Some patients did not comply with the protocol of the study. They did 
not complete the sampling schedule as specified and dropped out at different 
periods due to different reasons. Some of the patients live in areas far from 
the hospital with low economical and social status. They are mostly farmers, 
cultivators, wood cutters and herdsmen. The nature of long-term treatment 
and continuous follow up is new for those patients. They tend to discontinue 
the treatment and search other remedies e.g. cauterization and/or traditional 
medicine. Nonetheless, treatment of patients who dropped for other reasons 
was continued. It has been observed that some samples were also missing. 
This may be during sampling, storage or analysis. Some outlier values were 
observed that we do not have explanation for and were included in the 
analysis. Interpolation of data was performed regarding the missing samples. 
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Table 4.1 Reported values of ketoconazole pharmacokinetic parameters 
 
Species Reference Value 
Method 
of 
analysis 
Dose n 
Pharmaco
kinetic 
Parameter 
(Mean 
±SD) 
Human Nizoral® 
Monograph 
2.02 ± 
0.18* 
HPLC   400 mg 24 Tmax (h) 
Human Daneshmend et al. 
(1984) 
2.62 ± 
0.91 
HPLC       200 mg   
Human Daneshmend et al. 
(1984) 
3.00± 
0.76 
HPLC   400 mg   
Human Daneshmend et al. 
(1984) 
2.85± 
1.07 
HPLC   800 mg   
Rat Kotegawa et al. 
(1999)  
0.50 
±0.29 
EEG 10 
mg/kg 
4  
Human Mannisto et al. 
(1982) Fasting 
1.40  HPLC 200 mg   
Human Mannisto et al. 
(1982) Meals 
2.30  HPLC 200 mg   
Human Mannisto et al. 
(1982)    Orange   
juice 
1.80  HPLC 200 mg   
Human Sugar et al. (1987) 4.00 – 
6.00* 
HPLC 400 mg 160  
Human Huang et al. (1986) 1.00 – 
4.00* 
HPLC 200 mg 24  
Human The present study 2.33 ± 
0.52 
HPLC 400 mg 6  
Human The present study 2.17 ± 
0.41 
HPLC 800 mg 6  
Human Daneshmend et al. 
(1984) 
3.29 ± 
0.22 
 
HPLC 200 mg  Cmax  
(µg/ml) 
Human Stockley et al. 
(1986) 
3.20 ± 
1.80 
HPLC 200 mg 9  
Human Mannisto et al. 
(1982) Fasting 
4.10 ± 
0.30* 
HPLC 200 mg   
Human Mannisto et al. 
(1982)Meals 
2.30 ± 
0.30* 
HPLC 200 mg   
Human Mannisto et al. 
(1982)Orange juice 
3.60 ± 
0.20* 
 HPLC 200 mg   
Human Negroni et al. 
(1980) 
1.54 – 
3.12* 
HPLC   200 mg   
Human Robertson et al. 
(1980) 
1.60 – 
7.00* 
HPLC       200 mg   
Human Hay et al. (1980) 2.50 HPLC   200 mg   
Human Galimberti et al. 
(1980) 
1.56 – 
3.12* 
HPLC   200 mg   
Human Gascoigne et al. 
(1981) 
3.50 HPLC 200 mg   
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Human Huang et al. (1986) 1.50–
4.50* 
HPLC 200 mg   
Human Daneshmend et al. 
(1984) 
10.64 ± 
0.73 
 
 HPLC 400 mg   
Human Stockley et al. 
(1986) 
4.60 ± 
3.20 
 
HPLC 400 mg 9  
Human Espinel – Ingraff et 
al. (1981) 
3.42 HPLC 400 mg   
Human Daneshmend et al. 
(1981) 
6.50 HPLC 400 mg   
Human Gascoigne et al. 
(1981) 
5.50 HPLC 400 mg   
Human Sugar et al. (1987) 7.00 – 
17.00* 
HPLC 400 mg 160  
Human Daneshmend et al. 
(1984) 
 19.22 ± 
1.99 
HPLC 800 mg   
Human Nizoral® 
Monograph 
6.65 ± 
0.763* 
HPLC 400 mg 24  
Human Kotegawa et al. 
(1999) 
9.20 ± 
4.50* 
EEG 10 
mg/kg 
4  
Human The present study 9.08 ± 
3.96 
HPLC 400 mg 6  
Human The present study 17.21 ± 
7.53 
HPLC 800 mg 6  
Human Daneshmend et al. 
(1984) 
13.6 ± 
1.2 
 
 HPLC 200 mg  AUC∞ 
(µg.h/ml) 
Human Stockley et al. 
(1986) 
12.30 ± 
7.70 
 
HPLC 200 mg 9  
Human Daneshmend et al. 
(1984) 
59.2 ± 
6.20 
 
HPLC   400 mg   
Human Stockley et al. 
(1986) 
23.00 ± 
18.20 
  
HPLC       400 mg 9  
Human Daneshmend et al. 
(1984) 
151.20 ± 
16.60 
HPLC   800 mg   
Human Mannisto et al. 
(1982) Fasting 
14.40 ± 
2.21* 
HPLC   200 mg   
Human Mannisto et al. 
(1982)Meals 
8.60 ± 
1.33* 
HPLC 200 mg   
Human Mannisto et al. 
(1982)Orange juice 
13.40 ± 
1.30* 
HPLC 200 mg   
Human Nizoral® 46.161 ± 
7.135* 
HPLC 400 mg 24  
Rat Kotegawa et al. 
(1999) 
26.80 ± 
15.70* 
EEG 10 
mg/kg 
4  
Human The present study 62.34 ± 
31.03 
HPLC 400 mg 6  
Human The present study 121.56 ± 
71.52 
HPLC 800 mg 6  
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Human Daneshmend et al. 
(1984) 
1.43 ± 
0.08 
 
HPLC 200 mg  T1/2 (h) 
Human Stockley et al. 
(1986) 
3.10 ± 
1.90 
HPLC 200 mg 9  
Human Daneshmend et al. 
(1984) 
2.45 ± 
0.27 
HPLC 400 mg   
Human Stockley et al. 
(1986) 
3.50 ± 
1.70  
HPLC 400 mg 9  
Human Daneshmend et al. 
(1984) 
3.62 ± 
0.20 
HPLC 800 mg   
Human Mannisto et al. 
(1982)  
1.70 – 
2.00* 
HPLC 200 mg   
Human Brass et al. (1982) 2.00 – 
3.30* 
 HPLC 200 mg   
Human Badcock et al. 
(1987) 
3.30  HPLC 200 mg   
Human Huang et al. (1986) 7.50 – 
7.90* 
 200 mg 24  
Human Nizoral® 
Monograph 
3.47 ± 
0.40* 
HPLC 400 mg 24  
Rat Kotegawa et al. 
(1999) 
1.38 ± 
0.52* 
EEG 10 
mg/kg 
4  
Human The present study 4.24 ± 
1.87 
 HPLC 400 mg 6  
Human The present study 4.00 ± 
0.66 
 HPLC 800 mg 6  
Rat Kotegawa et al. 
(1999) 
0.45 ± 
0.18 
EEG 10 
mg/kg 
4 CL/F (L/h) 
Human The present study 8.78 ± 
6.85 
HPLC 400 mg 6  
Human The present study 8.79 ± 
5.57 
HPLC 800 mg 6  
Rat Kotegawa et al. 
(1999) 
0.89 ± 
0.57 
EEG 10 
mg/kg 
4 Vd/F (L) 
Human The present study 42.70 ± 
14.67 
HPLC 400 mg 6  
Human The present study 49.28 ± 
27.11 
HPLC 800 mg 6  
 
* Mean (± SE)   
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4.2. Pharmacokinetics of ketoconazole tablets; 400 mg regimen 
 
The mean (± SD) values of maximum drug concentration (Cpmax) after 
administration of first dose of 400 mg ketoconazole regimen was found to be 
9.08 ± 3.96 µg/ml, while that for last dose was 11.56 µg/ml. Our results were 
comparable to the values reported by Daneshmend et al, 1984 ( 10.64 ± 0.73 
µg/ml) and Sugar et al, 1987 ( 7.00 – 17.00 µg/ml) who used the same dose 
(Table 4.1). 
The mean values of time to reach Cpmax (Tmax) after administration of 
first dose 2.33 ± 0.52 h, range (2 - 3) h and last dose 6 h of 400 mg regimen 
are comparable with the values (Mean ± SE) of 2.02 ± 0.18 h reported in the 
Nizoral® Monograph, (1994) and 3.00 ± 0.76 h (Mean ± SD) reported by 
Daneshmend et al, (1984) . 
The mean value of AUC∞ for ketoconazole obtained after oral 
administration of first dose of 400 mg regimen was 62.34 ± 31.03 µg.h/ml 
(range 17.82 – 113.83 µg.h/ml). And that obtained after oral administration of 
last dose was 183.07 µg.h/ml. The values of AUC∞ reported in the literature 
(Mean ± SD) using the same dose are 46.161 ± 7.14 µg.h/ml (Nizoral® 
Monograph, 1994), 59.2 ± 6.2 µg.h/ml (Daneshmend et al, 1984) and 23.00 ± 
18.2 µg.h/ml (Stockley et al, 1986). Our results agree with the first two 
authors and show discrepancy with the last author. 
The mean values of CL/F for 400 mg ketoconazole regimen are 8.78 ± 
2.80 L/h (range 3.51 ± 22.45 L/h) and 1.09 L/h for first dose and last dose, 
respectively. The mean values of Vd/F for ketoconazole are in the sequence 
of 42.70 ± 5.99 L (range 22.47 – 49.35 L) and 13.55 L for first dose and last 
dose of 400 mg regimen. The values of clearance and volume of distribution 
reported by Kotegawa et al, (1999) were 0.45 ± 0.18 L/h/kg and 0.89 ± 0.57 L, 
respectively. The dose used by those authors is of 10 mg/kg in rat. Inter-
species differences is possible. 
The mean CL/F, calculated by using the AUC from a 200 mg 
ketoconazole solution, was 209.9 (± 82.9) ml/min, and the mean V/F was 
88.31 (± 68.72) liters, suggesting an extensive distribution of the drug in the 
body (Daneshmend et al.1983). The same author showed that the mean 
CL/F decreased as the dose increased. It decreased from 244.9 (+96.0) to 
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123.6 (± 31.4) to 80.8 (± 17.8) ml/min as the dose increased from 200 to 400 
to 800 mg, respectively; the differences in the CL/F between the 200 and 800 
mg doses and between the 200- and 400 mg doses were statistically 
significant 
The mean values of the elimination half - life (T1/2) for ketoconazole are 
4.24 ± 1.87 h (range 1.45 – 7.04 h) and 8.60 h for first dose and last dose of 
400 mg regimen. These values are in good agreement with a value of 3.5 ± 
1.70 reported by Stockley et al, (1986). However, they are lower than the 
value of 7.50 – 7.90 reported by Huang et al, (1986).  
 
4.3 Pharmacokinetics of ketoconazole tablets; 800 mg regimen 
 
For 800 mg ketoconazole regimen the mean values of Cpmax after 
administration of first dose were found to be 17.21 ± 7.53 µg/ml (range 9.38 – 
20.65 µg/ml) and those after last dose were 18.44 ± 7.35 µg/ml (range 11.26 
– 28.54 µg/ml). The values of these parameters are almost the same 
following the administration of the two doses. The values of Cpmax obtained 
for 800 mg ketoconazole regimen, agrees with previous observations (19.22 
± 1.99 µg/ml) reported by Daneshmend et al, (1984). 
The mean values of time to reach Cpmax (Tmax) after administration of 
first dose 2.17 ± 0.41 h, range (2 - 3) h and last dose 2.00 ± 0.82 h, range 1 - 
3 h of 800 mg regimen are comparable of 2.85 ± 1.07 h reported by 
Daneshmend et al, (1984) following the use of the same dose. 
The values (Mean ± SD) of AUC∞ for 800 mg ketoconazole regimen 
are in the sequence of 121.56 ± 71.52 µg.h/ml, range 41.27 – 252.19 µg.h/ml 
for first dose and 264.56 ± 136.96 µg.h/ml, range 87.97 – 378.30 µg.h/ml for 
last dose. The values reported in the literature are 151.2 ± 16.6 µg.h/ml 
(Daneshmend et al, 1984). 
The MRT for 800 mg ketoconazole regimen was 7.86 ± 3.28 h (range 
5.42 - 14.28 h) and 12.49 ± 5.29 h (range 5.49 - 17.08 h) for first and last 
doses, respectively.  
The mean values of CL/F for 800 mg ketoconazole regimen are 8.79 ± 
5.57 (range 3.17 – 19.38 L/h) and 3.18 ± 2.48 (range 1.59 - 6.82) L/h following 
first and last doses, respectively.  
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The mean values of Vd/F are in the order of 49.28 ± 27.11 (range 17.23 
– 96.61) L and 36.66 ± 40.14 (range 10.91 – 96.27) L for first and last doses 
of 800 mg regimen. 
The mean values of the elimination half - life (T1/2) for ketoconazole are 
4.00 ± 0.66 (range 3.23 – 4.98) h and 6.83 ± 2.15 (range 4.63 – 9.78) h for 
first dose and last dose 800 mg regimen, respectively. The values reported in 
the literature are 3.5 ± 1.70 (Stockley et al. 1986), 7.50 – 7.90 (Huang et al, 
1986) and 3.62 ± 0.2 h (Daneshmend et al, 1984) 
 
4.4. Comparisons of pharmacokinetic parameters of ketoconazole 
following administration of the two regimens 
Comparisons of pharmacokinetic parameters of ketoconazole following 
its administration as 400 mg and 800 mg regimens are shown in table 3.7. 
 
4.4.1. Comparisons following the administration of the first and last 
doses of 400 mg regimen 
The maximum plasma concentrations achieved after first dose and last 
dose were 9.08 ± 3.96 and 11.56 µg/ml, respectively. The corresponding 
mean values of Tmax were found to be 2.33 ± 0.52 and 6.0 h for the two dosing 
regimens. The values of Cpmax are comparable; however, those of Tmax are 
different. Statistical analysis was not performed since the data of the last dose 
is obtained from only one patient. 
The mean values of AUC∞ were found to be 62.34 ± 32.03 µg.h/ml for 
first dose and 183.08 µg.h/ml for last dose. 
The values for t1/2 were calculated as 4.24 ± 1.87 and 8.6 h following 
the administration of first and last doses of 400 mg, respectively. The t1/2 
increased following the administration of the last dose. 
The values of Cl/F and Vd/F were estimated as 8.78 ± 6.85 and 1.09 
L/h; 42.7 ± 14.67 and 13.55 L for the two doses. Both clearance and volume 
of distribution were decreased following the administration of the last dose. 
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4.4.2. Comparisons following the administration of the first and last 
doses of 800 mg regimen 
The peak concentrations reached after the administration of the first 
800 mg dose was 17.21 ± 7.53 µg/ml compared to 18.44 ± 7.35 µg/ml 
obtained after the last dose. There were no statistically significant differences 
in Cpmax between the tow doses (p = 0.4). The mean values of Tmax were 
found to be comparable between the two doses 2.17 ± 0.41 and 2.00 ± 0.82, 
respectively. There is no statistically significant difference in Tmax between the 
two doses (P = 0.36). These values are comparable with values reported in 
the literature. 
The mean values of AUC∞ were found to be 121.56 ± 71.52 µg.h/ml for 
first dose and 264.56 ± 136.96 µg.h/ml for last dose. These values were 
tested statistically and no significant differences were observed (P = 0.06). 
The values for t1/2 were calculated as 4 ± 0.66 h and 6.83 ± 2.15 h 
following the administration of 800 mg as first and last doses, respectively. 
Statistically significant differences were observed in t1/2 following repeated 
dose administration (P = 0.04). Our findings are in good agreement with the 
values (7.5 – 7.90 h) reported by Huang et al, (1986) who suggested a dose-
dependent increase in half life with increase of the dose and repeated 
ketoconazole administration. 
The physiological parameters Cl/F and Vd/F were estimated as 8.79 ± 
5.57 and 3.18 ± 2.48 L/h; 49.28 ± 27.11 and 36.66 ± 40.14 L following the 
administration of the first and last doses of 800 mg regimen. Decrease in both 
clearance and volume of distribution was observed following repeated dosing. 
These differences were tested statistically. No statistically significant 
differences were observed in volume of distribution. While the differences in 
clearance were found to be statistically significant between the two doses (P = 
0.03). Our results are in good agreement with the results published by Heel 
and coworkers (1982) who suggested an autoinhibition of ketoconazole 
metabolism on its long-term treatment in humans. 
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4.4.3. Comparisons following the administration of the first doses of 400 
and 800 mg regimens 
The peak concentrations achieved after 400 mg (9.08 ± 3.96 µg/ml) is 
almost double that following the administration of 800 mg ketoconazole (17.21 
± 7.53 µg/ml). This indicates that ketoconazole follow linear pharmacokinetic 
behavior at this dosing range. The mean values of Tmax were found to be 
comparable between the two dosing regimens (2.33 ± 0.52 and 2.17 ± 0.41, 
respectively). There is no statistically significant difference in Tmax between the 
two doses (P = 0.18). These values are comparable with values reported in 
the literature by Nizoral® Monograph, (1994) and Daneshmend et al, (1984) 
The mean values of AUC∞ were found to be 62.34 ± 31.03 µg.h/ml for 
400 mg regimen and 121.56 ± 71.52 µg.h/ml for 800 mg regimen. This is 
another indication for linearity of ketoconazole kinetics at the studied dosing 
regimens. 
The values for t1/2 were calculated as 4.24 ± 1.87 and 4 ± 0.66 h 
following the administration of 400 and 800 mg, respectively. No statistically 
significant differences were observed in t1/2 following increase of the dose (p = 
0.38). Our findings contradict the findings of 7.5 – 7.90 h reported by Huang 
et al, (1986) who reported a dose-dependent increase in half life with 
increase of the dose. 
The physiological parameters Cl/F and Vd/F were estimated as 8.78 ± 
6.85 and 8.79 ± 5.57 L/h ; 42.7 ± 14.67 and 49.28 ± 27.11 L for the two 
regimens. No statistically significant differences were observed in clearance 
or volume of distribution between the two regimens (P > 0.05). 
 
4.4.4. Comparisons following the administration of the last doses of 400 
and 800 mg regimens 
 The data obtained following the last dose was compared between the 
mean of four patients in the 800 mg regimen and only one patient in the 400 
mg regimen. Therefore statistical comparisons were not attempted. 
The peak concentrations reached following the administration of 400 
mg ketoconazole were 11.56 µg/ml compared to that of 800 mg ketoconazole 
(18.44 ± 7.35 µg/ml). Unlike comparisons of the first doses, the values of Tmax 
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following the administration of the last doses of the two dosing regimens (6.0 
and 2.00 ± 0.82, respectively) were different. 
The mean values of AUC∞ were found to be 183.07 µg.h/ml for 400 mg 
regimen and 264.56 ± 136.96 µg.h/ml for 800 mg regimen. While the 
estimated values of AUMC∞ were 2681.67 µg.h2/ml and 3644.23 ± 2930.57 
µg.h2/ml. 
The calculated parameters MRT, Ke and t1/2 were found to be 14.65 
and 12.42 ± 5.29 h; 0.08 and 0.11 ± 0.03 h-1; 8.6 and 6.83 ± 2.15 h for 400 
and 800 mg regimens, respectively. No reliable conclusions could be drawn 
from these observations because of the validity of the statistical test. 
The Cl/F and Vd/F were estimated as 1.09 and 3.18 ± 2.48 L/h; 13.55 
and 36.66 ± 40.14 L for the two regimens, respectively. There was increase in 
clearance and volume of distribution. Contrary to reports on the literature, the 
values of both Cl and Vd showed decrease following increase of the dose of 
ketoconazole (Huang et al, 1986). 
It has been observed that there is a double peak phenomena in the 
plasma concentration-time profile following the administration of the last dose 
of 800 mg regimen. The explanation of the double peak profile is reported by 
several authors in the literature. The double peaks in serum concentration, 
seen at higher doses of ketoconazole, raise the question of enterohepatic 
circulation or delayed absorption as suggested by Brass et al (1982).  
A random subgroup of 14 sets of samples from 12 patients showed a 
single peak in 9 sets (8 patients) and double peaks in 5 sets (4 patients). The 
possibility of demonstrating double peaks is obviously related in part to the 
number of samples obtained per day, but the fact that this phenomenon was 
frequently seen indicates that curves of concentration versus time after dose 
for individual patients are often irregular. Possible explanations include 
prolonged or irregular absorption and enterohepatic recirculation (Sugar et al. 
1987) 
Better absorption, nonlinear elimination, saturable first-pass 
metabolism, or a change in the volume of distribution of ketoconazole have 
also been suggested as explanations for the dose-dependent phenomena 
observed when doses increase from 100 to 400 mg (Daneshmend et al.1983). 
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Our results support the concept of a change in pharmacokinetics with 
chronic dosing. 
 
4.4.5. Comparisons of steady state levels of 400 and 800 mg regimens 
Plasma concentration fluctuated between minimum steady state 
concentrations (Cpssmin) of 2.68 ± 1.40 (CV%, 52.13%) and 4.18 ± 0.98 (CV%, 
23.52%) and maximum steady state concentrations (Cpssmax) of 8.00 ± 1.65 
(CV%, 20.67%) and 11.97 ± 3.24 (CV%, 27.07%) following the administration 
of the 400 mg and 800 mg ketoconazole regimens, respectively. 
The corresponding fluctuation at steady state (F, calculated as 
Cpssmax/Cpssmin) was found to be 3.98 ± 3.01 for the 400 mg regimen and 2.96 
± 0.93 for the 800 mg regimen (Table 3.8). 
 
4.5. Clinical outcome 
Medical treatment before surgery is recommended to ascertain high 
levels of ketoconazole in the circulation to minimize the chance of the 
organism local spread. Treatment with ketoconazole was continued in this 
study until the patients are clinically, serologically and radiologically cured. 
Clinical improvement is judged by reduction in the size of the mass and 
healing of the sinuses. Cure is considered when the skin becomes normal, the 
mass disappeared, the sinuses had healed and the organism is eliminated 
from the tissue. Prognosis of both treatment groups was satisfactory. In a 
dose of 200 mg twice daily, no significant side effects or biochemical 
abnormalities are seen. Except for dry mouth, experienced by the 800 mg 
regimen group, all patients were free of side effects. Liver function tests are 
carried out at baseline and at three months after treatment and no significant 
differences were observed. 
It has been mentioned earlier that surgical reduction of a bulky swelling 
without affecting the function of an affected bony lesion will certainly reduce 
the length of treatment. Both treatment groups showed reduction in bulky 
swelling and the lesions were well encapsulated. This allowed avoidance of 
aggressive surgical excision or amputation. 
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Only one patient in the 800 mg group experienced recurrence. 
Recurrence is more common after an incomplete course of medical treatment 
and there is a good chance for the organism to develop drug resistance.    
 
Conclusion 
It has been reported that the half-life of ketoconazole seems to be 
dose-dependent, increasing with increasing dose and after repeated dosing 
(Huang et al, (1986), Gascoigne et al, (1981). The slower elimination phase is 
also dose-dependent. Thus, long-term administration of ketoconazole can 
result in drug accumulation in humans (Heel et al, 1982) in rats and dogs 
(Gascoigne et al, 1981), and in mice (Whitehouse et al, 1990). The increasing 
dose-dependent half-life during long-term treatment in humans suggests 
autoinhibition of metabolism (Heel et al, 1982). Furthermore, ketoconazole 
displays nonlinear kinetics in both the volume of distribution and clearance as 
the dose is escalated (Huang et al, 1986). These observations correlate with 
the first-pass elimination of ketoconazole, with transient saturation of the drug-
metabolizing capacity of the liver at higher dosages (Heel et al, 1982, Huang 
et al, 1986 and Gascoigne et al, 1981). Also, ketoconazole has been 
purported to be extensively metabolized to a large number of metabolites, 
with hepatic microsomal enzymes playing the major role in the 
biotransformation reactions (Gascoigne et al, 1981 and, Daneshmend and 
Warnock, 1988). The metabolic pathways suggested in ketoconazole's 
biotransformation include oxidation, cleavage, degradation, and scission of 
the imidazole and piperazine rings, oxidative O-dealkylation, and aromatic 
hydroxylation (Heel et al, 1982, Gascoigne et al, 1981 and Medoff and 
Kobayashi, 1980). N-deacetyl ketoconazole appears to be the major 
metabolite reported in mice (Whitehouse et al, 1990). The accumulation of 
ketoconazole in mouse liver was minimal, whereas the hepatic levels of N-
deacetyl ketoconazole were significant (Whitehouse et al, 1994). 
The binding of ketoconazole in liver and adrenals is significant as 
shown by the liver to plasma partition coefficient of about 22 at a steady-state 
plasma concentration of 0.015 mg/L. Since this binding phenomenon is 
concentration dependent, as the tissues sites are saturating at elevated 
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concentrations, the volume of distribution of the drug decreases [Matthew et 
al. 1993]  
The hepatic clearance of ketoconazole is saturable such that AUC 
increases disproportionally with increasing dose [Matthew et al. 1993, 
Daneshmend et al.1984]. It was found that any dose resulting in 
concentrations above 0.5 mg/L would be anticipated to show mark 
nonlinearity [Matthew et al. 1993] 
Our findings are in good agreement with the above mentioned findings. 
They suggest the validity of the use of both dosing regimens of ketoconazole 
for the treatment of eumycetoma. However, the use of 800 mg dosing 
regimen is recommended to be use with great caution and only if necessary 
provided that continuous monitoring of the liver and kidney functions is 
grunted. Since there is a risk of dose-dependent pharmacokinetics which 
results in non-linear kinetics in clearance and volume of distribution. In 
addition to the possibility of autoinhibition of ketoconazole metabolism 
following increase of the dose and repeated dose administration. All this is 
expected to cause accumulation of ketoconazole in the body and might lead 
to toxicity. 
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